



Government **B**ioscience **G**rants

UPDATED MONTHLY

March 10, 2021

—
THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

PUBLISHED BY



Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com



www.G2Gconsulting.com



@G2Gconsulting





www.G2Gconsulting.com/bioscience-corner

GBG Report
Updated Monthly
 March 10, 2021

Upcoming Webinars: Join us **March 19 from 10:00-10:30 am EDT** for [G2G's GBG Report and Highlights Call & Screenshare](#) where we will take a deeper dive into funding opportunities listed below and **March 23 from 12:00-1:00 pm EDT** for [G2G's Preparing for the MHSRS Conference and Accessing DoD Opportunities](#) to learn insights into successfully submitting a MHSRS abstract and tips on navigating DoD opportunities.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
AGING (3)						
1.	Midlife in the United States Study (MIDUS) (U19 Clinical Trial Not Allowed) & Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed) (NIH)	PAR-21-156; 157	FOA 21-156 solicits applications to continue biopsychosocial integrations using multiple subprojects that collect data on sociodemographic and psychosocial factors, daily experience, cognitive capacities, biomarkers, neuroscience, and gene expression and that connect these content areas through innovative analyses. A central goal of the MIDUS study is to support data dissemination, provide user support of public use files, and encourage data use broadly by the scientific community. In conjunction, FOA 21-157, solicits an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with the MIDUS U19 studies to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD.	Letter of Intent Due: 3/26/21 10/18/21 Proposal Due: 4/26/21 11/18/21	Dependent upon proposal, for up to 6 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-156.html#_Section_II._Award_1 https://grants.nih.gov/grants/guide/pa-files/PAR-21-157.html#_Section_II._Award_1
2.	ACL National Falls Prevention Resource Center (HHS/ACL)	HHS-2021-ACL-AOA-FPSG-0019	This FOA awards one cooperative agreement, with two goals: Goal 1: Provide technical assistance, education, and resources to increase public awareness about the risk of falls and how to prevent them, as well as increase the number of older adults and adults with disabilities who participate in falls prevention programs. Goal 2: Support the development and enhancement of integrated, sustainable service networks that provide evidence-based falls prevention programs, as well as related services that address the social and behavioral determinants of health of older adults and adults with disabilities.	Proposal Due: 4/29/21	Up to \$1 million per year, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=329746 (Full Announcement in Related Documents Tab)



ALCOHOLISM (2)						
3.	Pre-Announcement Specialized Alcohol Research Centers (P50 Clinical Trial Optional) & Comprehensive Alcohol Research Centers (P60 Clinical Trial Optional) (NIH)	NOT-AA-21-004; 005	NIAAA intends to promote a new initiative by publishing FOAs to solicit applications to develop a broad-based Specialized Alcohol & Comprehensive Research Center programs to foster and conduct interdisciplinary, collaborative research on alcoholism, alcohol use disorder and the impact of alcohol on health and disease. and the impact of alcohol on health and disease. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.	Estimated Post Date: 5/1/21 Estimated Proposal Due Date: 11/15/21	Up to \$1.25 million, per award Dependent upon award mechanism	https://www.grants.gov/web/grants/view-opportunity.html?opId=331916 https://www.grants.gov/web/grants/view-opportunity.html?opId=331917
AMYOTROPHIC LATERAL SCLEROSIS (4)						
4.	FY21 Amyotrophic Lateral Sclerosis Research Program (ALSRP) (DoD/CDMRP)	W81XWH-21-ALSRP-TDA; TIA; CDA; TBPTA	The ALSRP supports support innovative and high-impact research into the development of effective treatments for Amyotrophic Lateral Sclerosis. Four different awards are anticipated for FY21. They include the following: (1) Therapeutic Development Award: Supports secondary preclinical validation and IND-enabling studies of therapeutics for ALS. Preliminary data are required, including efficacy of a lead molecule/class of compounds in at least one ALS-relevant model system, (2) Therapeutic Idea Award: Supports hypothesis-driven preclinical therapeutic development. Applications that include development of biomarkers in parallel to the main therapeutic effort, and that meet criteria outlined in the FOA will qualify for a higher level of funding, (3) Clinical Development Award: Supports correlative clinical research and leveraging of human-based ALS resources, (4) Therapeutic/Biomarker Pilot Trial Award: Supports exploratory clinical trials to demonstrate feasibility or inform the design of more advanced trials for the treatment or management of ALS.	Pre-Application Due: 4/9/21 Proposal Due: 7/15/21	Up to \$2 million, for up to 4 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/pa/FY21-ALSRP-TDA.pdf https://cdmrp.army.mil/funding/pa/FY21-ALSRP-TIA.pdf https://cdmrp.army.mil/funding/pa/FY21-ALSRP-CDA.pdf https://cdmrp.army.mil/funding/pa/FY21-ALSRP-TBPTA.pdf

ALZHEIMER'S DISEASE & DEMENTIA (2)						
5.	Triadic Interactions in Clinical Encounters Involving People with AD/ADRD, Clinicians, and Care Partners (R01 Clinical Trial Optional) (NIH)	RFA-AG-22-020	This FOA invites applications focused on triadic interactions and interpersonal processes between individuals with Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), clinicians, and care partners. NIA seeks to increase our understanding of the impact of such interactions on patient health and well-being outcomes. The goal of this initiative is to identify targets for the development of behavioral interventions to optimize interactions in clinical settings and help build and preserve strong and supportive caregiving relationships throughout all stages of AD/ADRD and across the continuum of care. To these ends, this FOA solicits basic research and Stage I behavioral intervention development clinical trials in two high-priority areas: (1) triadic communication and interpersonal relationships between patients, clinicians, and care partners; and (2) the clinical significance of dyadic processes in caregiving relationships between patients and care partners in the context of patient-caregiver-clinician encounters.	Letter of Intent Due: 5/23/21 Proposal Due: 6/23/21	Up to \$500,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-020.html#_Section II_Award 1
6.	AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed) (NIH)	PAR-21-141	Spurred by the mandates outlined in the National Plan to Address Alzheimer's disease and related dementias (AD/ADRD), clinical trials in the field of AD/ADRD have nearly doubled in the past three years. The intent of this FOA is to encourage applications that develop creative and innovative short courses to train the next generation of AD/ADRD clinical trialists in state-of-the-art clinical research skills. Competitive applications focused on educating prospective investigators on the conduct of non-pharmacological, behavioral, and social interventions relevant to AD/ADRD prevention, dementia care, treatment, and caregivers will address mechanisms of action and fidelity of delivery of interventions in the real world.	Proposal Due: 5/25/21	Up to \$400,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-141.html#_Section II_Award 1
AUTISM (2)						
7.	Pre-Announcement Autism Centers of Excellence: Networks (R01 & P50 Clinical Trial Optional) (NIH)	NOT-HD-21-006; 007	These FOAs solicit applications for autism centers of excellence (ACE) Networks and Centers. Investigators of current ACE Networks and others who believe that they have sufficient expertise and resources to coordinate and implement a multi-site research program are encouraged to begin consideration of applying for this initiative. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. These FOAs will utilize the R01 and P50 activity codes.	Estimated Post Date: 6/26/21 Estimated Proposal Due Date: 11/30/21	Up to \$1.5 million, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331894 https://www.grants.gov/web/grants/view-opportunity.html?opId=331915

			BIOMEDICAL DEVICE DEVELOPMENT (1)			
8.	Navy Multi-Topic 2021 - Advanced Biomedical Product Development in Support of Naval Operations (DoD/MTEC)	MTEC-21-10-Navy Multi Topic	<p>The purpose of the multiple topic area (“multi-topic”) RPP is focused on the advancement of engineering and medical prototypes and knowledge products related to a broad range of medical technological needs identified in the focus areas listed below. Relevance to the enhanced readiness and resilience of Navy and Marine Corps health and performance is a key feature of this RPP.</p> <ul style="list-style-type: none"> • Focus Area #1: Combat Casualty Wound and Infection Care: This area focuses on patient care at and through the continuum of care as well as products and services that sustain patient health in austere environments such as expeditionary, littoral, and deep water. • Focus Area #2: Enterotoxigenic Escherichia Coli (ETEC) Disease Research: This area focuses on medical technology and solutions that support the prevention and solutions that treat and/or cure ETEC. • Focus Area #3: Human Performance / Physiological Episodes (PEs). This area focuses on the prediction / improvement of health status and outcomes from various sources of combat related stressors that may include advanced biomedical electronics such as sensors and microelectronics and other medical technology solutions that mitigate the risk of PEs. 	White Paper Due: 3/22/21	Up to \$10 million, for up to 3 years	https://www.mtec-sc.org/wp-content/uploads/2021/02/21-10-NavyMultiTopic-RPP.pdf
			BROAD AGENCY ANNOUNCEMENTS (29)			
9.	BARDA Broad Agency Announcement (HHS/BARDA)	BAA-18-100-SOL-00003	<p>Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. This policy will continue indefinitely.</p> <p>COVID-19 response related Areas of Interest includes:</p> <ul style="list-style-type: none"> • Diagnostic assay for human coronavirus using existing FDA-cleared platforms • Point-of-care diagnostic assay for detection of SARS-CoV-2 virus • Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests • Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms • COVID-19 Therapeutics • AOI 17 Advanced Manufacturing Technologies 	White Papers Due: 10/31/21	Dependent upon proposal	https://beta.sam.gov/opp/30f25542d42b4e8aaefb69adfc4ac8dd/view https://www.mediccountermeasures.gov/barดา/barดา-baa

10.	BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA)	BAA-20-100-SOL-0002	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>BARDA is accepting submissions through the EZ-BAA for the following areas of interest (AOIs): AOI#1: Early Notification to Act, Control and Treat: seeking technologies to identify, characterize, and broadly adapt biological, biometric, behavioral and physiological signatures that can signal health security threat infections or exposures prior to symptoms. AOI#2: Infection Severity & Solving Sepsis: catalyzing technologies along the sepsis patient continuum to empower the patients, providers with a focus on technologies that address sepsis. AOI#5: Repurposing Drugs In Response to Chemical Threats: repurpose common therapeutics as medical counter measures and treat the symptoms associated with chemical agent exposure. AOI#6: Beyond the Needle: The goal of this program is to develop alternative vaccine technologies to make vaccinations easier to administer and more widely available. The goal is to reduce the burden of traditional vaccine delivery via needle and syringe on the healthcare system and supply-chain</p>	No Due Dates, open until 2/3/23	Up to \$750,000, per award	https://beta.sam.gov/opp/f2b87e34fecf47d0a48e9b03e8e826ff/view https://drive.hhs.gov/partner.html
11.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD)	W81XW H18SBA A1	<p>This BAA supports extramural R&D ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.</p>	<p>No Due Dates, open until 9/30/22</p> <p>Pre-application Required</p> <p>Full Proposal by invitation</p>	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/search-grants.html?keywords=W81XWH18SBA1 (Full Announcement in Related Documents Tab)

12.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD)	W911NF-18-S-0005	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Funding of R&D within ARI areas of interest will be determined by funding constraints and priorities set during each budget cycle. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.</p>	No Due Dates, open until 4/29/23 Full Proposal Required	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=304462 (Full Announcement in Related Documents Tab)
13.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD)	W911NF-17-S-0002-07	The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Science and Technology (S&T) Core Technical Competencies: Computational Sciences, Ballistics Sciences, Materials & Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network & Information Sciences and Human Sciences.	No Due Dates, open until 3/31/22	Dependent upon proposal	https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf
14.	Army Research Office Broad Agency Announcement Staff Research Program (DoD)	W911NF 20S0003	The ARO is soliciting proposals for Staff Research Program opportunities. The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.	No Due Dates, open until 2/19/25	Dependent upon proposal	https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf

15.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD)	W911NF-17-S-0003	<p align="center">BROAD AGENCY ANNOUNCEMENTS</p> <p>The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&T Campaigns located at www.arl.army.mil. These documents are subject to periodic refinements which may result in taxonomy inconsistencies. These inconsistencies should not affect the efficacy of the BAA to present a complete portfolio of essential ARL research.</p>	No Due Dates, open until 3/31/22	Dependent upon proposal	https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf
16.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH -BAA-2018	This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.	Expression of Interest accepted on a rolling basis though 5/30/22 Must be invited for full proposal	Dependent upon proposal and award type	https://www.grants.gov/web/grants/view-opportunity.html?opId=305999 (Full Announcement in Related Documents Tab)
17.	Air Force Office of Scientific Research Broad Agency Announcement (DoD)	FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation.	Proposals accepted on a rolling basis	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=305996 (Full Announcement in Related Documents Tab)

18.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD)	W81XW H-18-S-SOC1	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. Equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Projects may apply existing knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.</p>	<p>Submissions accepted through 7/31/23</p> <p>Submission of a pre-proposal is required</p>	Dependent upon proposal	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=307754</p> <p>(Full Announcement in Related Documents Tab)</p>
19.	Army Applications Lab BAA for Disruptive Applications (DoD)	W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.	<p>Submissions accepted through 5/1/24</p> <p>Submission of a pre-proposal is required</p>	Dependent upon proposal	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=315517</p> <p>(Full Announcement in Related Documents Tab)</p>
20.	United States Military Academy Broad Agency Announcement (DoD)	W911NF-20-S-0008	The USMA BAA identifies topics of interest to the USMA departments, directorates, and research centers and institutes. These groups focus on executing in-house research programs, with a significant emphasis on collaborative research with other organizations. The groups fund a modest amount of extramural research in certain specific areas, and those areas are described in this BAA. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.	Proposals accepted on a rolling basis	Dependent upon proposal	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=325932</p> <p>(Full Announcement in Related Documents Tab)</p>

21.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	<p align="center">BROAD AGENCY ANNOUNCEMENTS</p> <p>The National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories, each with core capabilities relevant to the threats posed by COVID-19. The NVBL is taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks.</p>	N/A	Dependent upon solicitation and proposal	https://science.osti.gov/nvbl?utm_medium=email&utm_source=FYI&dm_i=1ZJN,6UU9U,RBBVZ,X,RI3TV,1
22.	Broad Agency Announcement (BAA) C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research (DoD)	N66001-20-S-4702	The Naval Information Warfare Center, Pacific (NIWC Pacific) is soliciting white papers and proposals for competitive selection of basic research, applied research, advanced technology development, and advanced component development and prototype (hereinafter referred to as research). Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. Accordingly, proposals selected for award are considered to be the result of full and open competition and fully compliant with PL 98-369, "The Competition in Contracting Act of 1984." This BAA is for procurement contracts (hereinafter referred to as contracts), grants, cooperative agreements, and other transactions. Proposed research should investigate unique and innovative approaches for defining and developing next generation integratable C4ISR capabilities and command suites.	White Papers Due: 6/4/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=327529 (Full Announcement in Related Documents Tab)
23.	Broad Agency Announcement (BAA) Biological Technologies (DoD/DARPA)	HR00112 OS0044	The mission of BTO is to foster, demonstrate, and transition breakthrough research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences. BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, microbes as production platforms, and deep exploration of changing ecologies and environments on U.S. capabilities and resilience. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the DoD and addresses national security priorities.	Abstracts and proposals accepted on rolling basis until 4/22/21	Dependent upon proposal	https://beta.sam.gov/opp/4efd37762ed0475d871af927279f010d/view

24.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD)	W911QY 20R0022	BROAD AGENCY ANNOUNCEMENTS Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. This posting is not for a specific requirement - only to post the BAA solicitation so that interested parties can submit white papers and proposals for grants and other assistance agreements.	Proposals accepted on a rolling basis	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285 (Full Announcement in Related Documents Tab)
25.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD)	FA8650- 20-S- 6008	The Warfighter Medical Optimization Division (RHM) intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.	White papers accepted on rolling basis until 4/30/26	Up to \$49 million, per award	https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332 (Full Announcement in Related Documents Tab)
26.	Defense Sciences Office Office- wide BAA (DoD/DARPA)	HR00112 OS0048	The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security.	Proposals accepted on a rolling basis until 6/11/21	Dependent upon proposal	https://beta.sam.gov/opp/36d6bc789b364142a0f7a267017b06d9/view
27.	Transforming the Battlespace BAA (DoD/DARPA)	HR00112 OS0053	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts and proposals for applied research, advanced technology development, and platform demonstrations that aim to enable disruptive capabilities for future warfare. TTO projects usually define a reference operational system upfront, decompose critical technical risks, and define a demonstration around them. Use of off-the-shelf technology for lower risk subsystems reduces program cost and schedule but allows critical technologies to be matured and demonstrated.	Proposals accepted on a rolling basis until 6/11/21	Dependent upon proposal	https://beta.sam.gov/opp/03eeb369da1c4c0ea55ff4d1baed15af/view

28.	Research for the Department of Health and Human Services under Contracts, Other Transaction Agreements, & Technology Investment Agreements for Treatment and Protection from COVID-19 (HHS/OWS)	OWS-BAA-20-01	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>This BAA contemplates the award of procurement Contracts, TIAs, and OTAs in support of the mission areas to foster and/or conduct the development of FDA- approved medical products in support of Operation Warp Speed (OWS). OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD) to coordinate existing HHS-wide efforts, including the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA. As the purpose of this BAA is to identify the best available science in the identified areas of research interest.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	https://beta.sam.gov/opp/d3b19cfbad31430dab3880812ce2abf3/view
29.	FY2021 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology (DoD/ONR)	N00014-21-S-B001	The Office of Naval Research (ONR), ONR Global, and Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWLs broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.	Proposals accepted on a rolling basis until 10/30/21	Dependent upon proposal	https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements
30.	Information Innovation Office (I2O) Office-wide (DoD/DARPA)	HR001121S0010	This BAA seeks revolutionary research ideas for topics not being addressed by ongoing I2O programs or other published solicitations. Potential proposers are encouraged to review the current I2O programs (http://www.darpa.mil/about-us/offices/i2o) and solicitations (http://www.darpa.mil/work-with-us/opportunities) to avoid proposing efforts that duplicate existing activities or that are responsive to other published I2O solicitations. I2O programs are organized into four thrust areas: Proficient artificial intelligence (AI), Advantage in cyber operations, Confidence in the information domain & Resilient, adaptable, and secure systems.	Abstract Due: 9/23/21 Proposal Due: 10/28/21	Dependent upon proposal	https://beta.sam.gov/opp/b67c8910977b46f9828101812bb38617/view

31.	Broad Agency Announcement (BAA) Science & Technology for Advanced Manufacturing Projects (STAMP) (DoD/ONR)	N00014-21-S-B002	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>The Manufacturing Technology Program (ManTech) is the Defense Department’s investment mechanism for staying at the forefront of defense-essential manufacturing capability. The ManTech Program targets the needs of our warfighters and weapon system programs by helping to find and implement affordable low-risk solutions. The focus of this BAA is primarily on projects that continue to advance the systems engineering approach needed for the design, fabrication, and manufacture of structural components to address challenges in system weight, performance, affordability, and/or survivability. The intent is to bring together materials designers, materials suppliers, product designers, and manufacturers to collaborate on the design, production, and commercialization of novel affordable, manufacturable systems. Projects may include basic and applied research, technology and component development, and prototyping; but may also focus on manufacturing supply-chain technical support and integration, workforce development, and manufacturing education.</p>	Proposals accepted on a rolling basis until 10/30/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=329699 (Full Announcement in Related Documents Tab)
32.	Pre-Announcement SARS-CoV-2 (COVID-19) Program Activities Broad Agency Announcement (BAA) (HHS/OASH)	OS-PAW-20-001	The Office of the Assistant Secretary for Health (OASH) established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a BAA “to prevent, prepare for, and respond to coronavirus, for expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19” When posted, this FOA will guide the submission of white papers, which may be followed by full proposal submissions for funding consideration. Applicants will have the option of forgoing the white paper submission for direct submission of a full proposals. Applications will be accepted and reviewed on a rolling basis to address public needs.	Estimated Post Date: Spring 2021	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=328065
33.	Research Interests of the United States Air Force Academy (DoD)	USAFA-BAA-2021	USAFA’s Dean of Faculty Research Office is announcing to business and academia the intent to solicit white papers/proposals for USAFA research efforts through this BAA. USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. Research would essentially reveal mechanisms of existing natural systems, methods to incorporate present biological materials in nature, or disclose new capabilities within existing systems and/or materials.	Proposals accepted on a rolling basis	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=330175 (Full Announcement in Related Documents Tab)

34.	FY21 Young Investigator Program (DoD/ONR)	N00014-21-S-F001	<p align="center">BROAD AGENCY ANNOUNCEMENTS</p> <p>The Office of Naval Research (ONR) is interested in receiving proposals for its Young Investigator Program which seeks to identify and support academic scientists and engineers in their first or second full-time tenure-track academic appointment, who show promise for doing creative research. The objectives of this program are to attract outstanding faculty members to the Department of the Navy's Science and Technology research program, to support their research, and to encourage their teaching and research careers. Proposals addressing research areas (as described at www.onr.navy.mil) which are of interest to ONR program officers will be considered.</p>	Proposal Due: 3/26/21	Up to \$510,000, for up to 3 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=331358 (Full Announcement in Related Documents Tab)
35.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD)	W911NF-21-S-0007	The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. Domains of interest include 1) Personnel Testing & Performance, 2) Learning in Formal and Informal Environments, 3) Organizational Effectiveness and 4) Leader Processes and Measurement	White Papers Accepted Until: 5/15/22 Proposals Accepted Until: 8/4/22	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=331391 (Full Announcement in Related Documents Tab)
36.	Waveform Agile RF Directed Energy (WARDEN) (DoD/DARPA)	HR001121S0017	DARPA seeks proposals in the following areas of interest: High power microwave (HPM) amplifiers that use EM radiation to disrupt, disable, or damage targeted electronic components and circuits; theory and computational models to describe the coupling of EM radiation into complex enclosures via unintentional paths such as seams, apertures, and cable entry points and agile waveform techniques capable of producing disruptive effects on electronic components, devices, and sub-systems. In the Waveform Agile RF Directed Energy (WARDEN) program context, "agile waveforms" are time-dependent signals that combine frequency, amplitude, and/or pulse-width modulations to maximize coupling into a complex enclosure and are optimized to produce disruptive effects on internal electronic components and sub-systems. The WARDEN program is composed of three technical areas (TAs): TA1 HPM Traveling-wave Amplifier; TA2 Rapid Assessment & Numerical Generation of Electromagnetic Response (RANGER); and TA3 Agile Waveform Development.	Notice of Intent Due: 4/9/21 Proposal Due: 4/16/21	Dependent upon proposal, for up to 4 years	https://beta.sam.gov/opp/20104a5bdcb74ede858ea45a82345ae4/view

37.	Perceptually enabled Task Guidance (PTG) Broad Agency Announcement (DoD/DARPA)	HR00112 1S0015	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>Through this BAA, DARPA is soliciting innovative fundamental research proposals in the area of perceptually- enabled task guidance. The goal is to enable mechanics, medics, and other specialists to perform tasks within and beyond their skillsets by providing just-in-time feedback and instructions for physical tasks. We envision artificial intelligence (AI) technology that perceives the environment, reasons about physical tasks, and models the user, all in real-time. The AI will leverage commercially-available sensor technologies to see what the user sees and hear what the user hears, and will provide contextually relevant information and instruction to the user using augmented reality (AR). DARPA is soliciting these proposals to investigate innovative approaches that enable revolutionary advances in science. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.</p>	Proposers Day: 3/18/21 Abstract Due: 3/31/21 Proposal Due Date: 5/14/21	Dependent upon proposal, for up to 4 years	https://beta.sam.gov/opp/39d76d1a5c684eb0a6c834f17aaa678d/view
			BURN CARE (1)			
38.	Pre-Announcement FY21 Military Burn Research Program (MBRP) (DoD/CDMRP)	TBA	<p>The MBRP encourages applications proposing research that advances the development or refinement of interventions, technologies, or knowledge projects that will facilitate appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes. Applications submitted to the FY21 MBRP must address the following Focus Area: <i>Complex combat-related burns</i>: Development and/or validation of therapeutic interventions to treat military-relevant burn injury (heat, cold, chemical, or electrical) combined with other injuries including, but not limited to, hemorrhage, radiation, and/or polytrauma. Interventions or projects scalable to mass casualty events are of particular interest to the MBRP. Two award mechanisms are expected to be funded. They include the following: 1) Clinical Translational Research Award: Supports clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, preclinical, or clinical research findings to the care of the burn-injured patient, 2) Idea Development Award: Supports innovative research in the field of burn wound care.</p>	TBA	Up to \$1.5 million, for up to 4 years	https://cdmrp.army.mil/pubs/press/2021/21mbrppreann

CANCER (10)						
39.	FY21 Lung Cancer Research Program (LCRP) (DoD/CDMRP)	W81XW H-21-LCRP-CTRPA; IITRA	<p>Applications submitted to the FY21 LCRP must address one or more of the following Areas of Emphasis: (list is non-exhaustive)</p> <ul style="list-style-type: none"> Identify innovative strategies for prevention of the occurrence of lung cancer. Identify innovative strategies for the screening and early detection of lung cancer. Understand the molecular mechanisms of initiation and progression to lung cancer. <p>Two new awards remaining awards have been released. They are: 1) Clinical Translational Research Partnership Award which supports translational studies that include an interventional clinical trial & 2) Investigator-Initiated Translational Research Award which supports translational research that will develop promising ideas in lung cancer into clinical applications.</p>	<p>Pre-Application Due: 5/4/21 7/14/21</p> <p>Proposal Due: 7/28/21</p>	<p>Up to \$1.2 million, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<p>https://cdmrp.army.mil/funding/pa/FY21-LCRP-CTRPA.pdf</p> <p>https://cdmrp.army.mil/funding/pa/FY21-LCRP-IITRA.pdf</p>
40.	Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) (NIH)	RFA-CA-21-030	<p>This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies Program.</p>	<p>Letter of Intent Due: 5/2/21</p> <p>Proposal Due: 6/2/21</p>	<p>Up to \$475,000 per year, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-030.html#_Section_II_Award_1</p>

41.	Pre-Announcement Research Grants for the Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) & Coordinating Center (U01 Clinical Trial Not Allowed) (NIH)	NOT-CA-21-037; 038	<p style="text-align: center;">CANCER</p> <p>The FOA associated with NOT-CA-21-037 is expected to support transdisciplinary research projects on the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk. Responsive applicants should propose research that uses an observational or interventional study to emphasize a primary focus on research in humans. Research project grants should address one or more of the following main research objectives: (1) investigate the mechanistic role of metabolic dysregulation underpinning the link between obesity and cancer risk; (2) characterize an altered metabolic profile that identifies at-risk individuals; and (3) test interventions designed to modify obesity-associated metabolic pathways to decrease cancer risk. The FOA associated with NOT-CA-21-038 will fund a Coordinating Center to support the overarching goals of the “Metabolic Dysregulation and Cancer Risk Program” and to integrate efforts across research projects to facilitate transdisciplinary research. The Center's role and responsibilities are multifold, including, but not limited to: (1) providing administrative support; (2) facilitating cross-discipline collaboration(s) with funded investigators using creative and effective approaches; (3) coordinating efforts to optimizing synergy across funded research projects with guidance from the Steering Committee and NCI program staff; and (4) interacting with NCI program staff to support the short-term goals and objectives of the initiative.</p>	<p>Estimated Post Date: 5/1/21</p> <p>Estimated Proposal Due Date: 10/1/21</p>	<p>Dependent upon proposal</p> <p>Dependent upon award mechanism</p>	<p>https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-037.html</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-038.html</p>
42.	Pre-Announcement Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional) & (U24 Clinical Trial Not Allowed) (NIH)	NOT-CA-21-039; 040	<p>NCI will publish a FOA for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will also examine the complex mechanisms and effectors that direct the proliferation and expansion of tumor initiating cells and their progeny to initiate these cancers. The focus of the FOA will be on gastric and gastroesophageal junction (GEJ) adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestation or neoplasia. NCI will also publish a FOA for a Coordinating Center for the Program on the Origins of Gastroesophageal Cancers (U24). The Coordinating Center will be responsible for coordinating the activities of the gastroesophageal origin program and facilitating cross program collaborations and resources and models sharing.</p>	<p>Estimated Post Date: 5/1/21</p> <p>Estimated Proposal Due Date: 9/1/21</p>	<p>Up to \$600,000 per year, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p>https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-039.html</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-040.html</p>

43.	Pre-Announcement FY21 Peer Reviewed Cancer Research Program (PRCRP) (DoD/CDMRP)	TBA	<p style="text-align: center;">CANCER</p> <p>PRCRP provides funding for research into the following cancers: Bladder, blood, brain, beryllium associated, colorectal, endometrial, esophageal, germ cell, head and neck, liver, lymphoma, mesothelioma, metastatic, neuroblastoma. Five awards are expected to be funded. They include: (1) Behavioral Health Science Award: Supports innovative research and high-reward concepts that span the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer, (2) Career Development Award – Fellow Option: Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher, (3) Idea Award: Supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research, (4) Impact Award: Supports hypothesis-driven, high impact research and (5) Translational Team Science Award: supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research.</p>	TBA	<p>Up to \$2.5 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	https://cdmrp.army.mil/pubs/press/2021/21pcrppreann
44.	Pre-Announcement FY21 Prostate Cancer Research Program (PCRP) (DoD/CDMRP)	TBA	<p>Eight awards are expected to be funded under the FY21 PCRCP. They include the following: (1) Early Investigator Research Award: supports research opportunities focused on prostate cancer for individuals in the early stages of their careers, (2) Physician Research Award: supports a mentored research experience for physicians (3) Translational Science Award: supports advanced translational research (4) Health Disparity Research Award: supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer, (5) Idea Development Award: supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research, (6) Data Science Award: supports research where quantitative and analytical approaches, processes, or systems are developed to obtain knowledge from large and/or complex sets of prostate cancer data, (7) Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award: supports collaborations incorporating innovative and translational approaches that have the potential to make a major impact on one of the following PCRCP Overarching Challenges, and (8) Clinical Consortium Award: supports a consortium will facilitate the rapid execution of collaborative phase 2 or phase 1/2 clinical trials that will bring to market high-impact, novel therapeutic interventions that will significantly decrease the impact of prostate cancer.</p>	TBA	<p>Up to \$10 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	https://cdmrp.army.mil/pubs/press/2021/21pcrppreann

45.	Pre-Announcement FY21 Kidney Cancer Research Program (KCRP) (DoD/CDMRP)	TBA	<p style="text-align: center;">CANCER</p> <p>Seven awards are expected to be funded under the FY21 KCRP. They include the following: (1) Academy of Kidney Cancer Investigators – Early-Career Investigator Award: supports addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty, (2) Clinical Trial Award: supports hypothesis-based, early-phase clinical trials to test interventions that will have a major impact in the field of kidney cancer, (3) Clinical Research Nurse Development Award: Prepares nurses for active careers in collaborative clinical kidney cancer research and patient care, (4) Concept Award: supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer, (5) Idea Development Award: supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer, (6) Postdoctoral and Clinical Fellowship Award: Supports research opportunities focused on kidney cancer for individual in the early stages of their careers, and (7) Translational Research Partnership Award: supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.</p>	TBA	Up to \$2 million, for up to 4 years	https://cdmrp.army.mil/pubs/press/2021/21kcrpreann
			CENTRAL NERVOUS SYSTEM (7)			
46.	Notice of Special Interest (NOSI): Availability of Administrative Supplements for BRAIN Initiative Awardees to Support Resource Dissemination (NIH)	NOT-NS-21-014 PA-20-272	<p>The goal of this NOSI is to accelerate the scientific impact of the BRAIN Initiative through rapid dissemination of promising technologies and resources to the neuroscience research community via administrative supplements to currently awarded grants. This NOSI will support small dissemination efforts for which a clear value to the identified user group is demonstrated in the application. The proposed work must be within the scope of the original project of the eligible parent award but beyond the original dissemination plans included in the parent application. Projects may accomplish this goal by engaging in one or more of the following types of activities. This list is representative, but not exhaustive:</p> <ul style="list-style-type: none"> • Production and distribution of reagents • Services supporting the deployment of customized instrumentation based on end user need • Provision of state-of-art components, devices, or integrated systems distributed to end users <p>Use PA-20-272 to apply to this NOSI.</p>	Proposals accepted on a rolling basis	Up to \$100,000 per year, for up to 2 years	https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-014.html https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section II. Award 1

47.	Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace (NIH)	NOT-MH-21-125 PA-20-260; 265	<p style="text-align: center;">CENTRAL NERVOUS SYSTEM</p> <p>This NOSI encourages translation of the BRAIN Initiative supported technologies from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications that propose to further develop, optimize, validate and scale such technologies for commercial dissemination. Additionally, SBIR and STTR applications supporting the development and commercialization of novel technologies that fit within the mission of the BRAIN Initiative are encouraged. BRAIN Priority Areas were identified in the BRAIN 2025 Report; applications from SBCs that aim to commercialize technologies relating to these priority areas are encouraged: (1) Cell type, (2) Circuit Diagrams, (3) Monitor Neural Activity, (4) Interventional Tools, (5) Theory & Data Analysis Tools, (6) Human Neuroscience and (7) Integrated Approaches. Use PA-20-260 or PA-20-265 to apply to this NOSI.</p>	Letter of Intent Due: 4/5/21 9/5/21	Up to \$256,580, for up to 1 year (Phase I) & Up to \$1.7 million, for up to 2 years (Phase II)	https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-125.html https://grants.nih.gov/grants/guide/pa-files/PA-20-260.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/PA-20-265.html#_SectionII.Award1
48.	Pre-Announcement FY21 Spinal Cord Injury Research Program (SCIRP) (DoD/CDMRP)	TBA	<p>Applications to the FY21 SCIRP must address one or more of the following focus areas:</p> <ul style="list-style-type: none"> • Psychosocial issues relevant to people with SCI, their families, and/or their care-partners • Preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes • Identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies • Bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain • Rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after SCI <p>Three awards are expected to be funded. They include the (1) Clinical Trial Award: supports Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of SCI and its consequences, (2) Translational Research Award: supports studies that accelerate the movement of promising ideas in SCI research into clinical applications and (3) Investigator-Initiated Research Award: supports SCI-related research with the potential to make an important contribution to SCI research, patient care, and/or quality of life.</p>	TBA	Up to \$3 million, for up to 4 years Dependent upon award mechanism	https://cdmrp.army.mil/pubs/press/2021/21scirppreann

49.	Spinal Cord Injury Model Systems (HHS/ACL)	HHS-2021-ACL-NIDILRR-SIMS-0049	<p align="center">CENTRAL NERVOUS SYSTEM</p> <p>The SCIMS program is designed to provide research-based knowledge to support a multidisciplinary system of rehabilitation care specifically to meet the needs of individuals with SCI. To be eligible for a SCI Model Systems grant, an applicant institution must provide a continuum of care for people with SCI, including emergency medical services, acute care services, acute medical rehabilitation services, and post-acute services. SCIMS Centers must conduct site-specific and collaborative research. SCIMS Centers must also collect and contribute data to the SCIMS longitudinal database. SCIMS Centers will be funded at varying amounts up to the maximum award based on the numbers of database participants eligible for follow-up in the SCIMS longitudinal database.</p>	Letter of Intent Due: 4/13/21 Proposal Due: 5/8/21	Up to \$490,000 per year, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=330347 (Full Announcement in Related Documents Tab)
			CHRONIC DISEASE (1)			
50.	Pre-Announcement Expanding the National Approach to Chronic Disease Education and Awareness (CDC)	CDC-RFA-DP21-2112	<p>This competitive grant will complement or fill gaps in CDC’s National Center for Chronic Disease Prevention and Health Promotion’s (NCCDPHP) current priorities by supporting recipients for the following activities: 1) Data dissemination activities that support awareness for public health professionals; 2) Develop data collection tools to fill surveillance gaps; 3) Educational activities supporting public awareness; and 4) Educational activities supporting health professional screening, referral, and/or management. Collecting and disseminating reliable information on the impacts of chronic diseases is necessary to shape effective evidence-based clinical and population-level approaches for public health impact and health equity.</p>	Estimated Post Date: 5/2/21 Estimated Proposal Due Date: 7/2/21	Up to \$400,000, for up to 3 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=331872
			COLLABORATIVE RESEARCH (2)			
51.	Notice of Special Interest: Availability of Administrative Supplements to INBRE Awards to Fund Research Collaborations (NIH)	NOT-GM-21-016 PA-20-272	<p>NIGMS announces the availability of funds for Administrative Supplements to Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards. These funds are intended for existing INBREs to develop collaborations between investigators at the INBRE partner institutions, and investigators in research areas that are currently supported by one of the following programs:Centers of Biomedical Research Excellence, IDeA-Infrastructure for Clinical and Translational Research, IDeA co-funded R01s and R15s in their first or second year of awards, IDeA States Pediatric Clinical Trials Network awards, National Center for Advancing Translational Sciences Clinical and Translational Science Awards to institutions located in IDeA states.Use FOA PA-20-272 to apply to this NOSI</p>	Proposal Due: 4/30/21	Up to \$100,000, for up to 1 year	https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-016.html https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section II. Award 1

			COMBAT CASUALTY CARE (2)			
52.	Pre-Announcement interoperable Field Hospital (iFH) (DoD/MTEC)	TBA	The overall objective of the interoperable Field Hospital (iFH) effort is to create a tactical local area medical network to seamlessly receive, capture, and process secure medical information within deployed MTFs. The future operating environments, threats, and challenges envisioned in all domain operations (ADO) demand a tactical medical architecture that brings order to the complexities of the operating environment and provides operational commanders and medical staff with data to make informed decisions, increase patient survivability, and decrease morbidity from wounds suffered in the battlespace. The prototype developed under this upcoming RPP will fill these operational requirements by capturing data from field medical elements, Medical Evacuation (MEDEVAC) platforms, medical devices, patient monitors, and Medical Logistics (MEDLOG) databases in order to provide clinicians with the data required to make informed clinical decisions. The effective aggregation, analysis, and visualization of these data will eliminate the reliance on time intensive and manual processes and reduce burden to medical providers in order to increase efficiency when treating mass casualties (MASCAL) from a Combined / Joint force.	TBA	Dependent upon proposal, for up to 5 years	https://www.mtec-sc.org/solicitations/#Upcoming-Solicitations
53.	FY21 Combat Casualty Care Research Program (CCCRP) En Route Care Award (DoD/CDMRP)	W81XW H-21-DMRDP-ERCA	The intent of this award mechanism is to support development of highly innovative materiel and knowledge products to drive critical combat casualty care capabilities to the Warfighter in highly mobile, austere, and extreme environments where evacuation capabilities may be significantly delayed or unavailable. This Funding Opportunity aligns with the recently published Committee on En Route Combat Casualty Care (CoERCCC) top 10 research priorities including: medical documentation, clinical decision support, patient monitoring, transfer of care, transport physiology, maintenance of normothermia, transport timing, intelligent tasking, commanders' decision support, and unmanned transport, and focuses on research to knowledge and materiel to improve the en route care and patient movement from point of injury to definitive care by ground, air, and sea. The solutions under this Funding Opportunity will not be limited to military use. Knowledge and materiel products developed will have applications in civilian environments as well. Natural disasters, explosive events, accidents, and mass shootings can generate a surge of casualties and complex injuries that can mirror those seen on the battlefield.	Pre-Application Due: 3/31/21 Proposal Due: 6/23/21	Up to \$1.4 million, for up to 4 years	https://cdmrp.army.mil/funding/pa/FY21-DMRDP-JPC6-ERCA.pdf

CORONAVIRUS (17)						
54.	Pre-Announcement RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required) (NIH)	NOT-OD-21-065	The purpose of this Notice is to alert the community that NIH plans to publish a Research Opportunity (RO) as part of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative to solicit research on COVID-19 diagnostic testing approaches to safely return children and staff to the in-person school setting in underserved and vulnerable communities. The RO will consist of two phases: 1) a targeted solicitation to rapidly accelerate ongoing research already in place in the school setting; 2) an open solicitation to start new cohorts or approaches to gain data related to safe return. The targeted solicitation will be by invitation only and will include programs currently in place in the school setting; applications will be accepted through early March 2021 for FY21 funding with the goal to make awards no later than April 2021. Awards under this funding opportunity will be issued as Other Transaction Agreements (OT2), which are not grants, contracts or cooperative agreements. Other Transactions awards will involve active NIH program management. Furthermore, the OT funding mechanism provides NIH with the flexibility to design unique collaborations with private sector entities that may not have experience with commonly used assistance mechanisms such as grants and cooperative agreements.	TBA	TBA	https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-065.html
55.	Pre-Announcement Research Opportunity Announcements for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative (NIH)	OTA-21-015	NIH will publish a FOA as part of the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) initiative. The research will improve understanding of and develop strategies to prevent and treat post-acute manifestations of SARS-CoV-2 infection across the lifespan. Projects will be funded utilizing NIH's Other Transaction Authority (OTA), which offers flexibility and the ability to engage partners in collaborative innovation and problem solving. The goal of the PASC Initiative is to systematically advance our understanding of the recovery process after SARS-CoV-2 infection and to prevent and treat PASC. Toward these ends, the overall PASC Initiative is designed to address three fundamental scientific questions: - What is the biologic basis of the heterogeneity in recovery from SARS-CoV-2 infection? - For those patients who do not fully recover or develop new symptoms/sequelae, what is the incidence/prevalence, clinical spectrum, and underlying biology? - What interventions might improve recovery after SARS-CoV-2 infection and prevent long-term disability due to PASC?	Expected Proposal Due Date: March 2021	TBA	https://covid19.nih.gov/sites/default/files/2021-02/PASC-Pre-Notice.pdf

56.	Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration (NIH)	NOT-AG-21-016 PA-20-183; 184; 185; 194; 195; 196; 200	<p style="text-align: center;">CORONAVIRUS</p> <p>The specific research objectives of this NOSI is to inform applicants of NIA’s interest in basic and clinical mechanistic research on neurological and neurocognitive sequelae originating from SARS-CoV-2 infection and COVID-19 in aging and age-related neurodegeneration. NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer’s disease (AD) and AD-related dementias (ADRD). Animal and human studies are appropriate for this NOSI. This NOSI aims to promote collaborative and integrative efforts between investigators with different perspectives and backgrounds. Use the following FOAs to apply: PA-20-183, PA-20-184, PA-20-185, PA-20-194, PA-20-195, PA-20-196, Pa-20-200.</p>	Proposal Due: 6/5/21 10/5/21	Dependent upon proposal Dependent upon award mechanism	https://grants.nih.gov/grants/guide/notice-files/NOT-AG-21-016.html https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html#_SectionII.Award1
-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------	---------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

57.	Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy (NIH)	NOT-GM-21-021 PA-18-1935	<p style="text-align: center;">CORONAVIRUS</p> <p>NIGMS announces the availability of urgent competitive revisions to support vaccine hesitancy research relevant to SARS-CoV-2. This NOSI is intended to provide funds for the Institutional Development Award (IDeA) (P20, P30, and U54) and Native American Research Centers for Health (NARCH) (S06) grantees to expand the scope of their active grants. To understand the causes of the SARS-CoV-2 vaccine hesitancy and test intervention strategies to increase vaccine uptake, NIGMS encourages submission of applications for urgent competitive revisions to active IDeA and NARCH grants to address questions including but not limited to those listed below:</p> <ul style="list-style-type: none"> • What are the causes of vaccine hesitancy in IDeA states and the AI/AN communities? • What are the effective culturally specific and/or community competent approaches for reducing barriers and increasing the vaccination uptake and completion? • What interventions and strategies are most effective to increase the acceptance of vaccines among populations that experience health disparities? <p>Use PA-18-1935 to apply.</p>	Proposal Due: 4/30/21	Up to \$200,000, for up to 1 year	https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-021.html https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_Section II. Award 1
58.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NIH)	NOT-GM-21-019 PA-18-935	<p>NIGMS is issuing this NOSI to highlight the urgent need for modeling research on SARS-CoV-2 and COVID-19. NIGMS will accept the submission of applications for Competitive Revisions to all active NIGMS grants to address only the following research area: Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive computational models for the spread of SARS-CoV-2 and other related infectious agents. Efforts may include, for example, models for vaccination or other mitigation strategies, potential economic impacts and other topics related to transmission of SARS-CoV-2 variants. Applications in response to this NOSI must be submitted to PA-18-935.</p>	Applications accepted on a rolling basis until 12/15/21	Dependent upon proposal, for up to 1 year	https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-019.html https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_Section II. Award 1

59.	Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19 (NIH)	NOT-OD-21-071 PA-20-272 PA-18-935	<p style="text-align: center;">CORONAVIRUS</p> <p>The goal of this NOSI is to accelerate our understanding of the effects of SARS-CoV-2 infection and the COVID-19 pandemic on maternal mental health, well-being, functioning and quality of life. This research will seek to identify psychosocial and behavioral health risk factors related to the COVID-19 pandemic that affect mental health and functioning outcomes during pregnancy and up to one year postpartum and how they may contribute to increased pregnancy-related and pregnancy-associated morbidity and MM. IMPROVE will support research that addresses the impact of SRD in the context of the COVID-19 pandemic on maternal health outcomes for pregnant persons and up to one year postpartum. This new knowledge will advance the IMPROVE long-term goal of risk stratification approaches and mitigation strategies. NIH expects applicants to include a focus on underrepresented, underserved, and vulnerable pregnant/postpartum populations, address SRD, and to consider community-engaged research approaches. Use FOAs PA-18-935 or PA-20-272 to apply for this NOSI.</p>	Applications accepted on a rolling basis until 4/14/21	Up to \$2 million, per award	https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-071.html https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section_II._Award_1 https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1
			DEEP LEARNING (1)			
60.	Stimulating Collaborative Advances Leveraging Expertise in the Mathematical and Scientific Foundations of Deep Learning (SCALE MoDL) (NSF)	21-561	<p>Deep learning has met with impressive empirical success that has fueled fundamental scientific discoveries and transformed numerous application domains of artificial intelligence. Our incomplete theoretical understanding of the field, however, impedes accessibility to deep learning technology by a wider range of participants. Confronting our incomplete understanding of the mechanisms underlying the success of deep learning should serve to overcome its limitations and expand its applicability. his program complements NSF's National Artificial Intelligence Research Institutes and Harnessing the Data Revolution programs by supporting collaborative research focused on the mathematical and scientific foundations of Deep Learning through a different modality and at a different scale. When responding to this solicitation, even though proposals must be submitted through the Directorate for Mathematical and Physical Sciences, Division of Mathematical Sciences (MPS/DMS), once received, the proposals will be managed by a cross-disciplinary team of NSF Program Directors. PI teams must collectively possess appropriate expertise in three disciplines - computer science, electrical engineering, and mathematics/statistics.</p>	Proposal Due: 5/12/21	Up to \$1.2 million, for up to 3 years	https://www.nsf.gov/pubs/2021/nsf21561/nsf21561.htm#award_info

			DENTAL, ORAL & CRANIOFACIAL HEALTH (1)			
61.	NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) (NIH)	PAR-21-160	This FOA will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this FOA are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availability of funds.	Letter of Intent: 5/8/21 9/5/21 Proposal Due: 6/8/21 10/5/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-160.html#_Section II. Award 1
			DIABETES (1)			
62.	Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (T1D) (R01 Clinical Trial Not Allowed) (NIH)	RFA-DK-21-005	This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D. Projects responsive to this initiative could include (but are not limited to) the development of: <ul style="list-style-type: none"> • Cellular sentinels that can home to pancreatic tissue compartments to sense a developing disease environment; report on beta cell stress, inflammation or injury by producing a stable, measurable, but inert product that can be detected in body fluids • Collections of islet-homing synthetic immune clones, each equipped with a different sensing-response circuit and traceable reporter construct, for the PET imaging-enabled monitoring of various aspects of islet dysfunction and non-invasive disease staging in vivo • Islet-homing immune cells engineered to quell inflammation and reduce morbidity by contributing to tissue homeostasis and repair through the regulated production of natural or synthetic factors with trophic effects on beta cells to promote function, immunoprotection and/or replication • Engineered antigen-specific Treg cells that can home to the pancreatic islet or pancreatic draining lymph nodes and inhibit effector T cells in these compartments 	Letter of Intent Due: 5/22/21 Proposal Due: 6/22/21	Up to \$600,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-005.html#_Section II. Award 1

DRUG DEVELOPMENT & PHARMACOLOGY (2)						
63.	Drug Development Tools Research Grants (U01) Clinical Trial Optional (FDA)	PAR-21-178	The purpose of this FOA is to support research to continue the development of drug development tools (DDT) that have an accepted Letter of Intent (LOI) within a drug development tool qualification program within either CBER or CDER. Examples of DDTs may include but are not limited to: a biomarker used for clinical trial enrichment, a clinical outcome assessment (COA) used to evaluate clinical benefit, or an animal model used for efficacy testing of medical countermeasures under the Animal Rule. Increased public availability of qualified DDTs for specific contexts of use is anticipated to benefit the public health through (1) increased availability of effective drugs, (2) earlier access to medical therapies and (3) an enhanced knowledge of the drug under development.	Proposal Due: 5/25/21	Up to \$250,000 per year, for 1 year	https://grants.nih.gov/grants/guide/pa-files/PAR-21-178.html#_Section_II_Award_1
64.	Minor Use Minor Species Development of Drugs (R01) (FDA)	PAR-21-179	This NOFO solicits applications that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs. The following manufacturing studies, as part of the qualified safety and effectiveness studies, are eligible for funding if FDA/CVM/ONADE has already reviewed and concurred with the study protocol: (1) A study to evaluate the stability of a MUMS drug, (2) A study to validate analytical methods associated with the manufacture of a MUMS drug, (3) A study to determine the homogeneity/segregation of an animal feed bearing or containing a MUMS drug and (4) A study to validate methods for an animal feed bearing or containing a MUMS drug.	Letter of Intent Due: 6/14/21 Proposal Due: 7/30/21	Up to \$250,000 per year, for up to 3 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-179.html#_Section_II_Award_1
ENGINEERING (1)						
65.	NSF Boosting Research Ideas for Transformative and Equitable Advances in Engineering (BRITE) (NSF)	21-568	This solicitation seeks proposals that enable experienced researchers and scholars to forge new directions or to enter new fields by capitalizing or branching out of their established knowledge domains. All BRITE proposals are expected to address fundamental research that creates new knowledge in one or more CMMI program areas. BRITE proposals must identify key research outcomes and describe the research plans for the period of funding sought. Although collaborative proposals are not permitted and will be returned without review, the PI can include a collaborator in a limited role as senior personnel. The solicitation includes four funding tracks: Synergy, Pivot, Relaunch, and Fellow in support of experienced scientists and engineers.	Proposal Due: 5/25/21	Up to \$200,000 per year, for up to 5 years	https://www.nsf.gov/pubs/2021/nsf21568/nsf21568.htm#award_info

ENVIRONMENTAL HEALTH (2)						
66.	Pre-Announcement Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (NIH)	NOT-NS-21-030	The NIH Countermeasures Against Chemical Threats (CounterACT) program intends to publish a FOA to solicit applications to encourage Early Stage Investigators (ESI) to pursue exploratory/developmental, applied, proof of concept, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.	Estimated Post Date: 3/27/21 Estimated Proposal Due Date: 7/27/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=331921
67.	Pre-Announcement Enhancing Innovation and Capabilities of Environmental Public Health Tracking Network; Approaches to Data Modernization (CDC)	CDC-RFA-EH17-17020501 SUPP21	Using Tracking data and other program resources to inform public health action is explicit in the Tracking Program's mission, with the ultimate goal of reducing the burden of environmentally related health conditions. One approach in monitoring Tracking Program performance is by gathering information on how the Tracking Program has been able to drive public health actions within funded jurisdictions. With rapid changes in information technology and tools; changing data and information needs; changes in the population, disease, and environment, as well as the ability to continue to meet the growing needs of public health practitioners, researchers, and others, it is critical that the existing expertise, resources, and technical infrastructure in the Tracking Program and Tracking Network continue to support and enhance the availability, quality, timeliness, compatibility, and utility of existing hazard, exposure, and health effect data.	Estimated Post Date: 4/27/21 Estimated Proposal Due Date: 6/11/21	Up to \$250,000, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331895
FIREARM INJURY (2)						
68.	Firearm Injury and Mortality Prevention Research (R01/R21/R33 Clinical Trial Optional) (NIH)	PAR-21-191; 192	Research encouraged by these FOA is consistent with a broad public health approach to firearm injury and mortality prevention including: 1) identifying those at risk for firearm injury and mortality 2) development and initial piloting of theoretically-grounded programs to prevent firearm injury and mortality; and 3) implementation research to explore the barriers and facilitators to support broader adoption of effective programs. In addition to interventions delivered by healthcare providers and systems, this initiative encourages research delivered in community settings, and that integrates individual, family, interpersonal, community, and structural or system (e.g., criminal or juvenile justice, child welfare, drug courts) approaches to firearm injury and mortality prevention.	Letter of Intent Due: 3/30/21 Proposal Due: 4/30/21	Up to \$1.78 million, for up to 5 years Dependent upon award mechanism	https://grants.nih.gov/grants/guide/pa-files/PAR-21-191.html#_Section_II._Award_1 https://grants.nih.gov/grants/guide/pa-files/PAR-21-192.html#_Section_II._Award_1

FUNGAL DISEASE (1)						
69.	Pre-Announcement Global Fungal Disease Surveillance and Capacity (CDC)	CDC-RFA-CK21-2106	The outcome of this NOFO is to reduce illness and death due to fungal diseases and improve the clinical outcomes for patients with fungal disease. Activities supporting this goal include monitoring trends in fungal disease burden, improving diagnostic capacity and treatment availability, and raising awareness among the public about the threat of fungal diseases. Strategies for this NOFO are four-fold: increase fungal surveillance by building epidemiology and laboratory capacity; support identification of known and emerging fungal pathogens; promote workforce development and training in the prevention and control of fungal diseases; and monitor and evaluate the impact of these interventions and assess and refine performance metrics.	Estimated Post Date: 4/24/21 Estimated Proposal Due Date: 6/23/21	Up to \$300,000, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331731
GENE THERAPY (1)						
70.	Pre-Announcement AAV Vector manufacturing for diseases affecting very small populations (FDA)	FOR-FD-21-007	CBER seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors. Such innovations include the definition of critical quality attributes of AAV as vectors for gene therapy, development of advanced process analytics, development of a of non-proprietary AAV vectors, and demonstration of low-cost, non-proprietary GMP manufacturing methods for AAV vectors. This research will advance innovative manufacturing of AAV vectors for gene therapy. CBER anticipates that addressing the need for gene therapy products for diseases affecting very small populations will also lead to technical developments that will advance the entire field of gene therapy.	Estimated Post Date: Spring 2021	Up to \$600,000, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331721
HEALTHCARE DISPARITIES (1)						
71.	Pre-Announcement Understanding and Addressing the Impact of Structural Racism & Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional) (NIH)	NOT-MD-21-016	The National Institute on Minority Health and Health Disparities (NIMHD), with other NIH Institutes, Centers and Offices (ICOs), intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications on (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This FOA will utilize the R01 activity code. Details of the planned FOA will be released in Spring 2021.	Estimated Post Date: 4/9/21 Estimated Proposal Due Date: 8/20/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=331887

HEARING LOSS (9)						
72.	Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability (NIH)	NOT-DC-21-001 PAR-20-185; 194; 195; 260; 262; 265 PAR-21-063; 064	Hearing loss (HL) is a leading public health concern. Untreated HL significantly impacts communication abilities and quality of life and has serious psychosocial and economic ramifications. Approximately 17 percent of American adults, or 36 million people, report some degree of HL. Age-related hearing loss is of increasing public health concern as the older adult population grows. Globally, hearing loss has been identified as the fifth leading cause of years lived with disability. This NOSI encourages applications on HL and hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults. Appropriate studies may include but are not limited to the following: Population Based Studies, Innovative Models, Technologies & Collaborative and Interdisciplinary Research. Use any of the FOAs listed to apply to this NOSI.	Proposal Due: 6/5/21 6/16/21 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years Dependent upon award mechanism	https://grants.nih.gov/grants/guide/notice-files/NOT-DC-21-001.html https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1 https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_Section II. Award 1
HEMATOLOGY (1)						
73.	New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional) (NIH)	PAS-21-150	This FOA is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease.	Proposal Due: 6/5/21 10/5/21	Up to \$200,000 per year, for up to 3 years	https://grants.nih.gov/grants/guide/pa-files/PAS-21-150.html#_Section II. Award 1

IMAGING (2)							
74.	Notice of Special Interest (NOSI): Translation of Quantitative Imaging (QI) tools and Methods for the Academic Industrial Partnership (AIP) (NIH)	NOT-CA-21-032 PAR-20-155	The overall goal of this NOSI is to translate well-developed QI tools for potential utility to oncologists and radiologists who rely on cancer in vivo images for accurate diagnosis and treatment planning. Active collaborations between academia and industrial partnerships are expected to result in robust quality management controls, with continual interplay between the AIP QI team and clinicians, which will lead to the production of high-quality QI tools through several rounds of iterative optimizations and validation. Therefore, this NOSI for AIP is an ideal platform to initiate translation of well-developed QI tools for dissemination and integration into clinical oncology community workflow. <i>The research goals of this NOSI include:</i> (1) Translation of well-developed QI tools for treatment planning, predicting or measuring response to therapy as tools which can translate into clinical trial decision support and (2) Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing multi-site clinical trials. The activities that fall within the scope of this NOSI include: (1) validation and integration of well-developed Quantitative Imaging tools into the clinical workflow (2) the ultimate aim towards gaining FDA approval for tool commercialization. The academic investigators will actively collaborate with a industrial partner who will help refine a specific quantitative imaging tool chosen for its potential clinical utility with the goal of a well formulated plan as demonstrated by appropriately chosen objective performance targets. Use FOA PAR-20-155 to apply.	Proposal Due: 6/5/21 10/5/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-032.html https://grants.nih.gov/grants/guide/pa-files/PA-20-155.html#_Section II. Award 1	
IMMUNE-MEDIATED & INFECTIOUS DISEASES (2)							
75.	Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research (NIH)	NOT-AI-21-011 PA-20-195	This NOSI invites applications proposing innovative informatics/data science projects that seek to answer novel scientific questions and address knowledge gaps in basic, translational and clinical, immune-mediated and infectious diseases by using data in repositories and knowledgebases. The projects may combine data from a variety of repositories and/or knowledgebases funded by NIAID in addition to other sources, including controlled-access and private user-generated data. The research focus areas of the applications must include infectious diseases, emerging infections, basic immunology or immune-mediated disease (i.e. allergy, autoimmunity, or immune reactions associated with transplantation). Use PA-20-195 to apply to this NOSI.	Proposal Due: 6/16/21 10/16/21	Up to \$275,000, for up to 2 years	https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-011.html https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section II. Award 1	

INFLUENZA (1)						
76.	Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States (CDC)	CDC-RFA-IP21-2101	This NOFO continues work initiated under influenza cooperative agreements IP16-1603, IP16-1605, IP19-1902 and previous awards from years 2004 - 2015. These agreements were developed to enhance the ability and capacity of foreign governments to conduct surveillance for seasonal influenza and to detect and respond to pandemic influenza threats. The proposed NOFO complements current global pandemic preparedness work and seeks to further strengthen the capacity of national health authorities and partners to detect and respond to influenza outbreaks and on a broader scale to respond to respiratory pathogen outbreaks utilizing as needed the influenza surveillance systems as a surveillance base.	Proposal Due: 5/4/21	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=331960 (Full Announcement in Related Documents Tab)
MATERNAL HEALTH (8)						
77.	Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health (NIH)	NOT-EB-21-001 PA-20-260; 261; 262; 265; 272	The purpose of this NOSI is to inform potential applicants that the National Institute of Biomedical Imaging and Bioengineering and participating Institutes and Centers (ICs) invite SBIR/STTR applications to develop technologies or tools to quantitatively predict or indicate an increased risk for maternal morbidity and mortality (MMM). This NOSI is part of the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) initiative, which supports research to reduce preventable causes of maternal deaths and improve health for women before, during, and after delivery. This NOSI is intended to encourage interest in the small business community to develop various approaches, technologies, and tools to address the health issues of maternal morbidity and mortality by achieving a wide array of outcomes, such as 1) the identification, phenotyping, subtyping, and stratification of patients at a greater risk of MMM, 2) multi-level interventions to address racial disparities in MMM, and 3) clinical decision-making that considers social and cultural biases. Use any of the FOAs listed in the solicitation to apply to thi NOSI.	Proposal Due: 4/5/21 9/5/21	Up to \$256,580, for up to 1 years (Phase I) & Up to \$1.7 million, for up to 2 years (Phase II)	https://grants.nih.gov/grants/guide/notice-files/NOT-EB-21-001.html https://grants.nih.gov/grants/guide/pa-files/pa-20-260.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/pa-20-261.html#_SectionII.Award1 https://grants.nih.gov/grants/guide/pa-files/pa-20-262.html#_SectionII.Award1

78.	Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Clinical Centers (Collaborative UG3/UH3 Clinical Trial Required) & Multisite Resource and Coordinating Center (U24 Clinical Trial Required) (NIH)	RFA-HL-22-007; 008	<p style="text-align: center;">MATERNAL HEALTH</p> <p>FOA RFA-HL-22-007 invites applications for clinical or community sites to be part of a multi-center group- or cluster-randomized trial under the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program. ENRICH will aim to test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 years old) who are of low socioeconomic status (SES), live in low-resource rural or urban communities, or who are in diverse geographic regions of the U.S. with high burden of cardiovascular disease (CVD) risk factors. Specifically, this initiative will support multi-site interventions designed to determine if a CVH module delivered within the context of a home visiting program can enhance maternal and early childhood CVH. A companion FOA RFA-HL-22-008 encourages applications for a collaborating Resource Coordinating Center (RCC).</p>	<p>Letter of Intent Due: 5/11/21</p> <p>Proposal Due: 6/11/21</p>	<p>Up to \$3.9 million, for up to 7 years</p> <p>Dependent upon award mechanism</p>	<p>https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-007.html#_Section_II._Award_1</p> <p>https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-008.html#_Section_II._Award_1</p>
			MENTAL & BEHAVIORAL HEALTH (14)			
79.	Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required & R01 Clinical Trial Required) (NIH)	PAR-21-129; 130	FOA PAR-21-129 supports clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial, device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA supports multi-site trials that require participation of two or more collaborative sites for completion of the study (e.g., in order to increase sample size, accelerate recruitment, or increase sample diversity and representation). Support for fully powered effectiveness studies via a single R01 grant is provided through a separate FOA, PAR-21-130.	<p>Letter of Intent Due: 5/15/21 9/15/21</p> <p>Proposal Due: 6/15/21 10/15/21</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-129.html#_Section_II._Award_1</p> <p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-130.html#_Section_II._Award_1</p>

80.	Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) (NIH)	PAR-21-131	<p align="center">MENTAL & BEHAVIORAL HEALTH</p> <p>This FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects. In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale effectiveness trial.</p>	<p>Letter of Intent Due: 5/15/21 9/15/21</p> <p>Proposal Due: 6/15/21 10/15/21</p>	Up to \$450,000 for up to 3 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-131.html#_Section_II_Award_1
81.	Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) (NIH)	PAR-21-132	The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need.	<p>Letter of Intent Due: 5/15/21 9/15/21</p> <p>Proposal Due: 6/15/21 10/15/21</p>	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-132.html#_Section_II_Award_1
82.	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required) (NIH)	PAR-21-133	The purpose of this FOA is to encourage cooperative agreement applications to support early-stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early-stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy.	<p>Letter of Intent Due: 5/15/21 9/15/21</p> <p>Proposal Due: 6/15/21 10/15/21</p>	Dependent upon proposal, for up to 4 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-133.html#_Section_II_Award_1

83.	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required & R61/R33 Clinical Trial Required) (NIH)	PAR-21-134; 135	<p style="text-align: center;">MENTAL & BEHAVIORAL HEALTH</p> <p>The purpose of these FOAs is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, these FOA are intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms.</p>	<p>Letter of Intent Due: 5/15/21 9/15/21</p> <p>Proposal Due: 6/15/21 10/15/21</p>	<p>Dependent upon proposal, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-134.html#_Section_II._Award_1</p> <p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-135.html#_Section_II._Award_1</p>
84.	Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required & R61/R33 Clinical Trial Required) (NIH)	PAR-21-136; 137	<p>The purpose of these FOAs is to support the early-stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness. Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early-stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R33 FOA supports single-phased clinical trial awards, while the R61/R33 FOAs are intended to support biphasic high-risk applications.</p>	<p>Letter of Intent Due: 5/15/21 9/15/21</p> <p>Proposal Due: 6/15/21 10/15/21</p>	<p>Dependent upon proposal, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-136.html#_Section_II._Award_1</p> <p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-137.html#_Section_II._Award_1</p>
85.	Behavioral Health Workforce Development Technical Assistance and Evaluation (BHWD TAE) Program (HHS/HRSA)	HRSA-21-086	<p>HRSA's behavioral health workforce development programs train behavioral health professionals and paraprofessionals in the provision of integrated, interprofessional, OUD/SUD prevention, treatment, and recovery services, and create a well-trained behavioral health workforce pipeline committed to working in high need and high demand areas, and with rural and medically underserved communities. This notice announces the opportunity to apply for funding under the Behavioral Health Workforce Development Technical Assistance and Evaluation (BHWD TAE) Program. The goals of this program 1) Create community and academic partnerships to develop a behavioral health workforce that maximizes collaborative learning and 2) Build an educational and interconnected behavioral and public health infrastructure prepared to respond and provide treatment to those impacted by OUD and other SUD.</p>	<p>Proposal Due: 5/3/21</p>	<p>Up to \$2.5 million per year, for up to 4 years</p>	<p>https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=ba6be757-f0a6-46a2-8a12-defca1e3f529</p>

86.	Pre-Announcement Systems-Level Risk Detection and Interventions to Reduce Suicide Ideation and Behaviors in Black Children and Adolescents, and Underserved Populations (R01 & R34 Clinical Trial Optional) (NIH)	NOT-MH-21-185; 186; 187; 188	<p align="center">MENTAL & BEHAVIORAL HEALTH</p> <p>NIMH intends to promote new initiatives by publishing FOAs to solicit applications for research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide, suicidal ideation and behavior (SIB), and non-suicide self-injury (NSSI) specifically among Black children and adolescents. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in Spring 2021 with an expected application due date in Summer 2021. It will utilize the R01 and R34 activity codes. Two separate FOAs solicit applications for research to test the effectiveness of the aforementioned interventions among underserved children, adolescents and youth more generally.</p>	<p>Estimated Post Date: 4/25/21 4/30/21</p> <p>Estimated Proposal Due Date: 6/29/21</p>	<p>Dependent upon proposal, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=331918</p> <p>https://www.grants.gov/web/grants/view-opportunity.html?opId=331919</p> <p>https://www.grants.gov/web/grants/view-opportunity.html?opId=331884</p> <p>https://www.grants.gov/web/grants/view-opportunity.html?opId=331920</p>
			NEONATAL HEALTH (1)			
87.	Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional) (NIH)	PAR-21-115	<p>This FOA encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p>	<p>Letter of Intent Due: 5/5/21 9/5/21</p> <p>Proposal Due: 6/5/21 10/5/21</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/pa-files/PAR-21-115.html#_Section_II._Award_1</p>

NEUROSCIENCE (2)						
88.	Pre-Announcement Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3/U44 Clinical Trial Optional) (NIH)	NOT-NS-21-031; 032	Blueprint Neurotherapeutics Network (BPN) intends to publish FOAs for investigators seeking support from the Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics). Applicants will be encouraged to utilize a customized set of contract resources and consultants from the BPN-Biologics Network to help advance their neuroscience-focused biotherapeutic discovery and development projects into the clinic. This Notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Details of the planned FOAs will be published in Spring 2021.	Estimated Post Date: 4/10/21 Estimated Proposal Due Date: 8/10/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=331922 https://www.grants.gov/web/grants/view-opportunity.html?opId=331923
OCCUPATIONAL HEALTH (1)						
89.	Pre-Announcement NIOSH Training Project Grants (CDC)	RFA-OH-22-003	The National Institute for Occupational Safety and Health (NIOSH), CDC, invites grant applications for Training Project Grants (TPGs) that are focused on occupational safety and health training. NIOSH is mandated to provide an adequate supply of qualified personnel to carry out the purposes of the Occupational Safety and Health Act, and the TPGs are one of the principal means for meeting this mandate. The majority of TPGs are in academic institutions that provide high quality training in the core occupational safety and health disciplines of industrial hygiene (IH), occupational health nursing (OHN), occupational medicine residency (OMR), occupational safety (OS), as well as allied disciplines.	Estimated Post Date: 4/10/21 Estimated Proposal Due Date: 10/26/21	Up to \$250,000, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331596
OPIOIDS & SUBSTANCE ABUSE (5)						
90.	Research Grants to Develop or Identify Effective Strategies to Prevent Overdose Involving Illicit Stimulants and Polysubstance Use Involving Stimulants (CDC)	RFA-CE-21-002	The CDC is soliciting investigator-initiated research that will support the identification of effective strategies for state, community, or systems-level implementation to prevent fatal and nonfatal overdoses involving illicit stimulants as well as polysubstance use and overdose involving illicit stimulants. This NOFO is intended to support research on one of the following objectives: (1) Conduct a process and outcome evaluation of new or adapted strategies, programs, or policies that can be implemented at the state, community, or systems-level to prevent illicit stimulant use or fatal and nonfatal overdose involving illicit stimulants, or polysubstance use or overdose involving illicit stimulants (2) Assess risk and protective factors for illicit stimulant use, use disorder, and overdose that can contribute to the development or adaptation of intervention strategies.	Proposal Due: 4/12/21	Up to \$725,000, per year, for up to 3 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=329359 (Full Announcement in Related Documents Tab)

91.	Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01-Clinical Trial Optional) (NIH)	RFA-DA-22-010	<p style="text-align: center;">OPIOIDS & SUBSTANCE ABUSE</p> <p>The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research. Current anti-retroviral therapies also have problems with drug toxicity, bioavailability, and have not been formulated for sustained release. Long term sustained delivery is needed among people with substance use disorders where compliance with an anti-retroviral therapy regimen may be problematic. To address these issues the development of improved reagents or technologies to enable targeted delivery of reagents to particular CNS regions or cell types is of great interest. Such delivery systems would improve our ability to monitor or manipulate HIV and SUD processes and could serve as the foundation for improved future therapeutics for HIV and/or SUD.</p>	<p>Letter of Intent Due: 9/25/21</p> <p>Proposal Due: 10/25/21</p>	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-010.html#_SectionII.Award1
92.	Medication Assisted Treatment - Prescription Drug and Opioid Addiction (HHS/SAMHSA)	TI-21-006	<p>The SAMHSA Center for Substance Abuse Treatment (CSAT) is accepting applications for the Medication-Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder (OUD) seeking or receiving MAT. Desired outcomes for this program are: 1) increase in the number of individuals with OUD receiving MAT; and 2) decrease in illicit opioid drug use and prescription opioid misuse at six-month follow-up. MAT, using one of the FDA-approved medications for the maintenance treatment of OUD is a required activity of this program</p>	<p>Proposal Due: 4/27/21</p>	Up to \$525,000 per year, for up to 5 years	https://www.samhsa.gov/sites/default/files/grants/pdf/fy-21-mat-pdoa-foa.pdf
93.	HEAL Initiative: Notice of Special Interest (NOSI) Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies (NIH)	NOT-NS-21-025 PA-20-272	<p>This NOSI provides an opportunity for clinical trials and studies funded by the Helping to End Addiction Long-Term (HEAL) initiative to address challenges of recruitment, retention and engagement of populations suffering from pain and opioid use disorder. NIH will support supplements to current HEAL awards that would either 1) enhance their patient, community, and other stakeholder engagement efforts or 2) improve recruitment, retention and inclusion of participants from U.S. racial and ethnic minority populations; or 3) both, as appropriate for a particular study. This supplement program is not intended to support research on basic processes but rather to implement strategies to enhance stakeholder engagement and diversity and inclusion in HEAL clinical studies. Activities proposed must be within the scope of the approved aims of the parent award.</p>	<p>Proposals Accepted until: 4/30/21</p>	Up to \$375,000, per award	https://grants.nih.gov/grants/guide/notice-files/not-ns-21-025.html https://grants.nih.gov/grants/guide/pa-files/pa-20-272.html#_SectionII.Award1

ORGAN TRANSPLANTATION (2)						
94.	Lung Transplant Consortium - Clinical Centers & Data Coordinating Center (U01/U24 - Clinical Trial Not Allowed) (NIH)	RFA-HL-22-002; 003	FOA 22-002 seeks applications from lung transplant clinical centers (CCs) to form a cooperative multi-site Lung Transplant Consortium (LTC). The LTC will support CCs in conducting observational and complementary mechanistic clinical research studies that aim to understand the impact of site-specific lung transplant selection criteria and clinical management strategies on donor lung utilization and/or early post-transplant outcomes such as the development of primary graft dysfunction (PGD) and acute lung allograft dysfunction in recipients. Each CC application must consist of a multidisciplinary investigative team that includes a lung transplant surgeon and a lung transplant pulmonologist and be comprised of primary and subsites that have a combined annual lung transplant volume of at least 100 transplants. FOA 22-003. invites applications to serve as the Data Coordinating Center (DCC) that will support the research activities of a cooperative multi-site LTC. The primary responsibility of the DCC will be to oversee the conduct of multiple observational and complementary mechanistic clinical research studies involving lung transplantation performed under a common research protocol by awarded CCs within the LTC.	Letter of Intent Due: 5/15/21 Proposal Due: 6/15/21	Up to \$700,000 per year, for up to 5 years Dependent upon award mechanism	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-002.html#_Section_II_Award_1 https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-003.html#_Section_II_Award_1
PAIN MANAGEMENT (2)						
95.	Pre-Announcement HEAL Initiative: Analgesic Development & Planning Studies for Initial Translational Efforts (U19 Clinical Trial Not Allowed) (NIH)	NOT-NS-21-033; 034	NINDS intend to promote a new initiative by publishing a FOA (NOT-21-033) to solicit applications for team-based research projects that develop assays, screens and propose early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and/or validation of pharmacodynamic markers and efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies will also be responsive. Additionally, NINDS intends to publish another FOA (NOT-21-034), to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015	Estimated Post Date: 3/1/21 Estimated Proposal Due Date: 4/27/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=331883 https://www.grants.gov/web/grants/view-opportunity.html?opId=331924

			PATIENT-CENTERED RESEARCH (6)			
96.	Optimizing Infrastructure for Conducting Patient-Centered Outcomes Research: PCORnet, The National Patient-Centered Clinical Research Network -- Phase 3 -- Cycle 1 2021 (PCORI)	N/A	This FOA describes the scope of work for the PCORnet CRNs for Phase 3 and available funding. CRNs are system-based networks that include hospitals and community based-practices, which routinely and securely collect individual patient-level data. CRN characteristics include: (1) coverage of large, diverse, defined populations unselected for a particular disease or condition, (2) Improvement of health systems, (3) The ability to efficiently contact patients for the purposes of recruitment, (4) Demonstrated ability to partner with patients and other stakeholders, (5) involvement of the healthcare system leadership in governance, (6) Willingness to serve as a national data infrastructure resource, (7) Capacity to support large comparative effectiveness trials, (8) Capacity to embed research activity within healthcare systems, (9) Clear, proven policies to maintain data security, patient privacy, and confidentiality, (10) Ability to advance the quality and availability of complete and comprehensive data sets and (11) Ability to streamline subcontracting processes for research involving multiple sites.	Proposal Due: 4/6/21	Up to \$7.5 million, for up to 3 years	https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-1-PCORnet-Phase-3-PFA.pdf
97.	Engagement Award: Stakeholder Convening Support -- April 2021 Cycle (PCORI)	N/A	The Stakeholder Convening Support offers funding for multi-stakeholder convenings, meetings, and conferences that align with PCORI's mission and facilitate expansion of PCOR/CER through collaboration around such efforts. Within this announcement, we express a special area of interest in maternal morbidity and mortality. Please see below for further detail. In addition, PCORI accepts and welcomes Engagement Award: Stakeholder Convening Support LOIs on all topics related to bringing together diverse stakeholders to explore issues related to PCOR/CER, or communicate PCORI-funded research results to targeted end-user audiences that fall within the guidelines of the program	Proposal Due: 4/1/21	Up to \$100,000, for up to 1 year	https://www.pcori.org/sites/default/files/PCORI-engagement-award-SCS-PFA-april-2021-cycle.pdf
98.	Engagement Award: Dissemination Initiative -- April 2021 Cycle (PCORI)	N/A	The Engagement Award: Dissemination Initiative will give organizations and communities the opportunity to propose either: (1) Building Capacity for Dissemination projects to lay the groundwork for disseminating and implementing PCORI-funded evidence through organizations with strong ties to end-user audiences, such as patients, clinicians, communities, and others who can use this information to inform healthcare decisions or (2) Active Dissemination projects aimed at spreading awareness and increasing knowledge of PCORI-funded evidence, targeted directly to end-user audiences, such as patients, clinicians, communities, and others who can use this information to inform healthcare decisions.	Letter of Intent Due: 4/1/21 Proposal Due: 7/12/21	Up to \$250,000, for up to 2 years	https://www.pcori.org/sites/default/files/PCORI-engagement-award-DI-PFA-april-2021-cycle.pdf

99.	Eugene Washington PCORI Engagement Award: Capacity Building (PCORI)	N/A	<p style="text-align: center;">PATIENT-CENTERED RESEARCH</p> <p>This funding announcement offers an opportunity for organizations and community groups to continue to build capacity and skills for patient-centered outcomes research and comparative clinical effectiveness research (PCOR/CER). PCORI is receptive to LOIs and applications to the Engagement Award: Capacity Building encompassing a wide range of research support project topics. In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects:</p> <ul style="list-style-type: none"> • Projects that support organizations with strong ties to patients, caregivers, clinicians, and/or other stakeholders who can engage as partners in PCOR/CER. • Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER. • Projects that support the expansion of use or adoption of existing engagement tools and resources whenever possible 	<p>Letter of Intent Due: 4/1/21</p> <p>Proposal Due: 7/12/21</p>	<p>Up to \$250,000, for up to 2 years</p>	<p>https://www.pcori.org/sites/default/files/PCORI-engagement-award-CB-PFA-april-2021-cycle.pdf</p>
100.	Eugene Washington PCORI Engagement Award Special Cycle: Building Capacity for PCOR/CER in Intellectual and Developmental Disabilities (PCORI)	N/A	<p>This opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health outcomes related to intellectual and developmental disabilities. Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest. In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects:</p> <ul style="list-style-type: none"> • Projects that focus on building the knowledge, competencies, and abilities of patients and other stakeholders to be meaningful partners in PCOR/CER with researchers throughout the research process, from topic selection through design and conduct of research to dissemination or implementation of results. • Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER. • Projects that support the expansion of use or adoption of existing engagement tools and resources to build capacity for PCOR/CER in a new population or geographic area. 	<p>Proposal Due: 5/24/21</p>	<p>Up to \$250,000, for up to 2 years</p>	<p>https://www.pcori.org/sites/default/files/PCORI-engagement-award-building-capacity-IDD-PFA-special-cycle-2021.pdf</p>

101.	Eugene Washington PCORI Engagement Award Special Cycle: Building Capacity for PCOR/CER for Topics Related to COVID-19 (PCORI)	N/A	<p style="text-align: center;">PATIENT-CENTERED RESEARCH</p> <p>This special funding opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health outcomes related to COVID-19. Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest. This is an opportunity to explore and address the urgent and unique needs to build capacity for stakeholder engagement in PCOR/CER specifically related to:</p> <ul style="list-style-type: none"> • Long-term effects of post-acute COVID-19; • Impact of COVID-19 on disproportionately affected populations; • Impact of COVID-19 on social isolation and loneliness (mental health and well-being); and • Engaging, educating, and promoting informed decision making around COVID-19 vaccines. 	Proposal Due: 5/24/21	Up to \$200,000, for up to 18 months	https://www.pcori.org/sites/default/files/PCORI-engagement-award-building-capacity-COVID19-PFA-special-cycle-2021.pdf
			RESEARCH INFRASTRUCTURE (7)			
102.	Defense University Research Instrumentation Program (DURIP) (DoD/AFOSR/ONR)	FOA-AFRL-AFOSR-2021-0002 W911NF-21-S-0004 N00014-21-S-F002	DURIP is designed to improve the capabilities of accredited US institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. Proposals must address the impact of the equipment or instrumentation on an institution's ability to educate students through research in disciplines important to DoD missions. DoD interests include the areas of research supported by the Air Force Office of Scientific Research (AFOSR), Army Research Office (ARO) and the Office of Naval Research (ONR).	Proposal Due: 5/14/21	Up to \$1.5 million, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331857 https://www.grants.gov/web/grants/view-opportunity.html?opId=331862 https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements

103.	Pre-Announcement Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases and Sjogren's Syndrome & Technology/ Analytic Cores and Research Management Unit (Clinical Trials Not Allowed) (NIH)	NOT-AR-21-013; 014	<p style="text-align: center;">RESEARCH INFRASTRUCTURE</p> <p>This Notice is to inform the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Allergy and Infectious Disease (NIAID), National Institute of Dental and Craniofacial Research (NIDCR), and Office of Research on Women's Health (ORWH) intend to issue a Funding FOAs for opportunities under the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: (1) Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases and Sjogren's Syndrome (2)Technology and Analytic Cores (TACs) and Research Management Unit (RMU). These FOAs will use the UC2 (High Impact Research and Research Infrastructure Cooperative Agreement Programs) grant mechanism. This notice is being provided to allow potential eligible applicants sufficient time to assemble teams and develop competitive and responsive projects. Details of the planned FOA will be provided in March 2021.</p>	<p>Estimated Post Date: 3/22/21</p> <p>Estimated Proposal Due Date: 7/1/21</p>	Dependent upon proposal	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=331888</p> <p>https://www.grants.gov/web/grants/view-opportunity.html?opId=331889</p>
104.	Notice of Special Interest (NOSI): Administrative Supplements for Equipment Purchases for NIGMS-funded Center Facilities, Core Facilities & for R01, R35, and R37 Awardees (NIH)	NOT-GM-21-029; 030	<p>NIGMS announces the availability of funds for administrative supplements to the following NIGMS-funded centers and resources:</p> <ul style="list-style-type: none"> • IDeA Networks of Biomedical Research Excellence (INBRE) • Centers of Biomedical Research Excellence (COBRE) • Mature Synchrotron Resources for Structural Biology • Biomedical Technology Research Resources • NIGMS Community, Regional, and National Scientific Resources • Collaborative Program Grant for Multidisciplinary Teams • Native American Research Centers for Health (NARCH) • Consortia/Centers/Network for Cryoelectron Microscopy • Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR) <p>Administrative supplements are also available for NIGMS-funded R01, R35, and R37 awards. These funds are intended for the purchase of needed equipment that will enhance user access to and impact of the resource and are within the scope of the parent project. Use PA-20-272 to apply for these NOSIs.</p>	<p>Proposal Due: 4/8/21</p> <p>4/30/21</p>	Up to \$250,000, for up to 1 year	<p>https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-029.html</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-030.html</p> <p>https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section II. Award 1</p>

SMALL BUSINESS DEVELOPMENT (7)						
105.	2021 Build to Scale Program (DOC/EDA)	EDA-HDQ-OIE-2021-2006827	EDA awards grants through the Build to Scale Program for activities designed to develop and support regional innovation initiatives. The Build to Scale Program invites organizations who are aiding companies in developing the next generation of technologies to apply for funding. These organizations may be operating initiatives to unlock investment capital across a region or sector, operating programs to accelerate company growth, empowering the next generation of entrepreneurs, and/or enabling technology commercialization. Under the Build to Scale Program, EDA is soliciting applications for two separate competitions: (1) the Venture Challenge, (2) the Capital Challenge	Proposal Due: 4/29/21	Up to \$1.5 million, for up to 3 years	https://www.eda.gov/files/oie/b2s/FY21-Build-to-Scale-NOFO-FINAL.pdf
106.	Advanced Manufacturing Project (DOC)	MBDA-OBD-2021-2006811	The Minority Business Development Agency (MBDA) will provide assistance to support innovative projects seeking to promote and ensure the growth of minority enterprises. The MBDA Advanced Manufacturing Project (AMP) program provides technical assistance and business development and manufacturing assistance services to minority business enterprises (MBEs). The AMP awards will be used to identify, screen, promote, and refer MBEs to specialized advanced manufacturing programs, and to provide technical and business development services. The technical assistance and business development services will generate increased financing and contract opportunities for MBEs and will assist MBEs in creating and retaining jobs. The AMP awardees also will assess regulatory changes pertaining to manufacturing in domestic and global markets, economic impact, and need for minority manufacturers.	Proposal Due: 4/8/21	Up to \$400,000 per year, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=331880 (Full Announcement in Related Documents Tab)
107.	Small Business Technology Transfer (STTR) Program Phase I Second Window Submissions (NSF)	21-563	NSF SBIR and STTR Program Phase I proposers are REQUIRED to submit a three-page "Project Pitch" that outlines the project objectives, technological innovation and associated technical risks. A small business must receive an official invitation via the Project Pitch process to submit a full proposal to this solicitation. The Project Pitch gives NSF the ability to review for appropriateness to the NSF SBIR/STTR Phase I program prior to the full proposal submission process, ensuring that proposers do not expend time or resources preparing full proposals that are clearly not aligned with the solicitation requirements. Details regarding this process as well as how to submit a Project Pitch can be found in section V.A of the full solicitation.	Submission window open until 6/3/21	Up to \$256,000, for up to 12 months	https://www.nsf.gov/pubs/2021/nsf21563/nsf21563.htm#award_info

108.	Small Business Innovation Research (SBIR) Technology Transfer (STTR) Program Phase II Second Window Submissions (NSF)	21-565; 566	<p align="center">SMALL BUSINESS DEVELOPMENT</p> <p>The NSF SBIR/STTR Program funds advanced research and development. The program is designed to provide non-dilutive financing and entrepreneurial support at the earliest stages of company and technology development. Small business may apply for a NSF Phase II SBIR or STTR award only if it has received an NSF Phase I award, and only for continued research toward commercialization of the technology developed under the Phase I award. Small businesses are eligible to submit a Phase II proposal between 6 and 24 months after the start date of their relevant NSF SBIR/STTR Phase I award. Reference the Phase I award notice for the exact start date of the Phase I award.</p>	Submission window open until 6/3/21	Up to \$1 million, for up to 2 years	https://www.nsf.gov/pubs/2021/nsf21565/nsf21565.htm?org=NSF#awd_info https://www.nsf.gov/pubs/2021/nsf21566/nsf21566.htm?org=NSF#awd_info
109.	Notice of Special Interest (NOSI): Administrative Supplements to STTR Regional Technology Transfer Accelerator Hubs (NIH)	NOT-GM-21-017 PA-20-272	NIGMS announces the availability of funds for an Administrative Supplement to an NIGMS-funded STTR Regional Technology Transfer Accelerator Hub (UT2) to provide business training for directors and staff of biomedical research core facilities funded by the Institutional Development Award (IDeA) Program . This award supports the development and delivery of a curriculum that introduces business fundamentals and best operational practices that will help improve the effectiveness and sustainability of the large number of IDeA-supported core facilities. Use FOA PA-20-272 to apply to this NOSI	Proposal Due: 4/30/21	Up to \$50,000, for up to 1 year	https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-017.html https://grants.nih.gov/grants/guide/pa-files/pa-20-272.html#_Section_II_Award_1
			STEM EDUCATION & WORKFORCE DEVELOPMENT (20)			
110.	Future Manufacturing (NSF)	21-564	Future Manufacturing supports research and education of a future workforce to enable new manufacturing capabilities that do not exist today. Future Manufacturing will require major advances in technologies and algorithms for the synthesis and production of new materials, chemicals, devices, components and systems of assured quality with high yield at reasonable cost. It will require new advances in artificial intelligence and machine learning, new cyber infrastructure, new approaches for mathematical and computational modeling, new dynamics and control methodologies, new ways to integrate systems biology, synthetic biology and bioprocessing, and new ways to influence the economy, workforce, human behavior, and society. Among this array of technologies and potential research subjects, three thrust areas have been identified for support in FY 2021 under this solicitation: Future Cyber Manufacturing Research, Future Eco Manufacturing Research, and Future Biomanufacturing Research.	Proposal Due: 5/14/21	Up to \$3 million, for up to 4 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=331521

111.	Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34) (NIH)	PAR-21-146	<p>STEM EDUCATION & WORKFORCE DEVELOPMENT</p> <p>The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs. This FOA provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-active institutions</p>	Proposal Due: 5/26/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-146.html#_Section_II._Award
112.	Developing Novel Engineering Design Methodologies for the Classroom, the Department of Defense, and Industry (DoD)	USAFA-BAA-2021-CALL-0001	<p>This call is focused on research to develop state-of-the-art design methodologies for design teams that produce innovative designs and demonstrate their feasibility for warfighting and other applications. These methodologies should have specific application to cadet capstone teams. The ultimate goal of the research is to enable cadets to generate innovative solutions to challenging projects and demonstrate the feasibility of their novel engineering designs that the customer may further develop. Research should support the full design lifecycle which may include research thrusts related to concept generation research, state of the art detailed design technology and methods, and research that guides solutions into production and operational use phases. Recipient will be expected to collaborate with Mechanical Engineering faculty to draft and publish scholarly research papers describing the research effort.</p>	White Paper Due: 3/18/21	Dependent upon proposal, for up to 4 years	https://www.grants.gov/web/grants/view-opportunity.html?opId=331549 (Full Announcement in Related Documents Tab)
113.	Maximizing Access to Research Careers (T34) (NIH)	PAR-21-147	<p>The goal of the Maximizing Access to Research Careers (MARC) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This FOA provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields.</p>	Proposal Due: 5/26/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-147.html#_Section_II._Award

114.	NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed) (NIH)	RFA-DE-22-001	<p>STEM EDUCATION & WORKFORCE DEVELOPMENT</p> <p>The objective of the NIDCR Award for SOAR is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years. The goal of this new initiative is to provide sustained and flexible support to NIDCR-funded investigators, who are in their mid-career stage, to conduct exceptionally innovative research with extraordinary potential for improving dental, oral, and craniofacial health.</p>	Letter of Intent Due: 6/8/21 Proposal Due: 7/8/21	Up to \$650,000 per year, for up to 8 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-001.html#_Section_II_Award_1
115.	NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U24 Clinical Trial Not Allowed) (NIH)	RFA-RM-21-019	The purpose of the NIH FIRST Coordination and Evaluation Center is to coordinate and facilitate the development of strategies with FIRST Cohort awardees to conduct a comprehensive evaluation of the FIRST program. The program will test the primary hypothesis that a cohort model of faculty hiring, sponsorship, continual mentoring, and support for professional development, embedded within an institution implementing evidence-based practices to create academic cultures of inclusive excellence, will achieve significant improvements in metrics of institutional culture and scientific workforce diversity. Evidence supports that diversity positively impacts scientific discovery through improved problem-solving, innovation, prediction, evaluation, verification, and strategization. Implementing and sustaining cultures of inclusive excellence has the potential to be transformational for the biomedical research workforce.	Letter of Intent Due: 3/23/21 Proposal Due: 4/23/21	Up to \$11.4 million, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-019.html#_Section_II_Award_1
116.	NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed) (NIH)	PAR-21-149	This FOA provides support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research. Programs should be designed to enhance the breadth and depth of training in NINDS mission areas by incorporating didactic, research and career development components in the context of a defined scientific theme. Programs may support basic, clinical and/or translational research. Components of programs supported by this FOA include mechanisms to ensure a thorough understanding of experimental design, strong statistics and analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences.	Letter of Intent Due: 4/25/21 Proposal Due: 5/25/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-149.html#_Section_II_Award

117.	Scholarships in STEM Network (NSF)	21-569	<p>STEM EDUCATION & WORKFORCE DEVELOPMENT</p> <p>To support collaboration within the S-STEM network, NSF will fund two types of investments: An S-STEM Resource and Evaluation Center (S-STEM-REC) and several S-STEM Research Hubs (S-STEM-Hub). The S-STEM Network(S-STEM-Net) will collaborate to create synergies and sustain a robust national ecosystem consisting of multi-sector partners supporting domestic low-income STEM students in achieving their career goals, while also ensuring access, inclusion, and adaptability to changing learning needs. This network will also synthesize current achievements and investigate evolving barriers to the success of this student population. It will also disseminate the context and circumstances by which interventions and practices that support graduation of domestic low-income students pursuing careers in STEM are successful.</p>	<p>Letter of Intent Due: 4/26/21</p> <p>Proposal Due: 6/16/21</p>	Up to \$3 million per year, for up to 5 years	https://www.nsf.gov/pubs/2021/nsf21569/nsf21569.htm#award_info
118.	Advancing Innovation and Impact in Undergraduate STEM Education at Two-year Institutions of Higher Education (NSF)	PD 21-7980	NSF's Education and Human Resources Directorate seeks to significantly enhance its support for research, development, implementation, and assessment to improve STEM education at the Nation's two-year colleges. NSF encourages bold, potentially transformative projects that address immediate challenges facing STEM education at two-year colleges and/or anticipate new structures and functions of the STEM learning and teaching enterprise. This program description is a targeted approach for advancing innovative and evidence-based practices in undergraduate STEM education at two-year colleges. It also seeks to support systemic approaches to advance inclusive and equitable STEM education practices.	Proposal Due: 5/10/21	Dependent upon proposal	https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505899&org=NSF&more=Y#more
119.	Notice of Special Interest (NOSI): Supplements for NIGMS Training, Research Education, and Career Development Grants to Develop Curricular, Training, and Evaluation Activities (NIH)	<p>NOT-GM-21-022; 023; 024; 025; 026; 027</p> <p>PA-20-272</p>	<p>NIGMS invites eligible institutions with NIGMS training (T32, T34), certain research education (R25), or institutional career development (K12) awards to apply for administrative supplements to develop and implement curricular, training, or administrative activities to:</p> <ul style="list-style-type: none"> Enhance laboratory safety curriculum and a culture of safety in biomedical research training environments (NOT-GM-21-027) Promote safe and inclusive biomedical research training environments (NOT-GM-21-026) Enhance undergraduate biomedical research training (NOT-GM-21-025) (T34 and R25 undergraduate programs only) Enhance program evaluation capacity (NOT-GM-21-024) Enhance mentor training (NOT-GM-21-023) Promote wellness and resilience (NOT-GM-21-022) <p>Use FOA PA-20-272 to apply for these initiatives.</p>	Proposal Due: 4/15/21	Up to \$80,000, for up to 1 year	<p>https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-022.html</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-023.html</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-024.html</p>

120.	Notice of Special Interest (NOSI): Administrative Supplements to Support Undergraduate Summer Research Experiences (NIH)	NOT-GM-21-028 PA-20-272	<p align="center">STEM EDUCATION & WORKFORCE DEVELOPMENT</p> <p>NIGMS announces the availability of funds for Administrative Supplements to NIGMS-funded R01, R35, and R37 awards. These funds are intended for support of undergraduate students who are considering pursuing biomedical research careers by providing authentic research experiences in cutting-edge scientific environments during the summer. For this supplement program, undergraduate students with a demonstrated interest in or desire to pursue research in health-related sciences, may participate in a research project during the summer months. The research experiences can be conducted remotely or in-person, depending on the institutional regulations. This experience is separate from any requirement of the regular academic program. The student may be affiliated with either the applicant institution or another academic institution. Administrative supplements must support work within the scope of the original project. Use FOA PA-20-272 to apply for these initiatives.</p>	Proposal Due: 4/15/21	Dependent upon proposal, for up to 10 weeks	https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-028.html https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_SectionII.Award1
121.	Notice of Special Interest (NOSI): NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional) (NIH)	NOT-MH-21-150 PA-20-272	<p>The goal of this Notice of Special Interest (NOSI) is to help MD/PhDs move more efficiently and effectively from the period of clinical training to the next stage of their research careers by supporting focused, protected research time during residency and/or clinical fellowship. The proposed research experience must be an integral part of the approved, ongoing research of the parent grant and must have the potential to contribute significantly to the candidate's research career. To ensure the flexibility of research opportunities, the specific plan and scope of the research experience may vary depending on such factors as the year in residency, the nature of the parent grant, the candidate's technical skillset and goals, and the candidate's available effort. Use FOA PA-20-272 to apply for these initiatives.</p>	Proposal Due: 4/1/21	Up to \$75,000, per award	https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-150.html https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_SectionII.Award1

TOBACCO RESEARCH (2)						
122.	Data Standards for Tobacco Research and Scientific Review Program (U24) Clinical Trial Not Allowed (FDA)	RFA-FD-22-002	The FDA Center for Tobacco Products is encouraging applications for projects to expedite development of data standards and terminologies to facilitate tobacco research, scientific review, harm reduction, and information exchange. The primary objective is to facilitate the development of non-proprietary, consensus-based, standards for use in studies of tobacco products. Projects may focus on solutions to general data standards development and implementation challenges and/or on specific concepts, domains or areas where standardization is needed.	Letter of Intent Due: 5/1/21 Proposal Due: 6/1/21	Up to \$250,000 per year, for up to 2 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-002.html#_Section II._Award_1
123.	Tobacco Regulatory Science (R01 Clinical Trial Optional) (FDA)	RFA-OD-21-002	The purpose of this FOA is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.	Letter of Intent Due: 5/14/21 Proposal Due: 7/14/21	Up to \$500,000 per year, for up to 5 year	https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-002.html#_Section II._Award_1
TRANSLATIONAL RESEARCH (2)						
124.	Notice of Special Interest (NOSI): Availability of Administrative Supplements for Submission of Tissue Chip Data to the Microphysiology Systems Database (MPS-Db) (NIH)	NOT-TR-21-019 PA-20-272	This NOSI informs current awardees that the National Center for Advancing Translational Sciences (NCATS) is providing an opportunity for supplemental funding to support deposition of data generated from tissue chips (also known as microphysiological systems, or “organs on chips”) into the NCATS-funded Microphysiology Systems Database (MPS-Db). Data that is responsive to the following criteria is of specific interest for deposition into the MPS-Db (non-exhaustive): <ul style="list-style-type: none"> • Data that represents new tissues, organs or disease models to the MPS-Db • Data representing disease models that are not yet represented in the MPS-Db, e.g., opioid use disorders, neurodevelopmental disorders, rare diseases, etc. • Data that can be aligned with clinical datasets which are accessible through the MPS-Db, e.g., on biomarkers, patient subgroups including pediatric populations, etc. Use FOA PA-20-272 to apply to this NOSI.	Proposal Due: 4/2/21	Up to \$35,000, for up to 1 year	https://grants.nih.gov/grants/guide/notice-files/NOT-TR-21-019.html https://grants.nih.gov/grants/guide/pa-files/pa-20-272.html#_Section II._Award_1

TROPICAL MEDICINE (2)						
125.	Tropical Medicine Research Centers & Coordinating Center (U01 Clinical Trial Not Allowed) (NIH)	RFA-AI-21-004; 005	FOA RFA-AI-21-004 solicits research applications focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment and control of select Neglected Tropical Diseases (NTDs) in endemic areas. Tropical Medicine Research Centers (TMRCs) are intended to advance NIAID's global research effort by targeting research endeavors to: develop novel diagnostic, prevention and therapeutic strategies adapted for the unique needs of low and middle-income countries create and sustain in-country research capacity; stimulate scientific collaboration and global partnerships; provide opportunities for junior and early-stage investigators to conduct research on NTDs; and facilitate sample sharing to support translational research to develop or evaluate new drugs, diagnostics, vaccines, therapeutics, and/or vector control strategies. RFA-AI-21-005 solicits applications for a TMRC Coordinating Center which will coordinate efforts across the TMRCs related to data management, data and specimen sharing, scientific collaboration, creation and maintenance of a virtual sample repositior and organizing annual meetings.	Letter of Intent Due: 5/18/21 Proposal Due: 6/18/21	Up to \$500,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-004.html#_Section_II_Award_1 https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-005.html#_Section_II_Award_1
VACCINE DEVELOPMENT (3)						
126.	Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed) (NIH)	RFA-AI-21-006	The purpose of this FOA is to solicit applications to expand basic research on non-polio enteroviruses (NPEV) that will inform the development of pan-enterovirus vaccines and broad-spectrum antivirals against enteroviruses A, B, C, and D. Given the paucity of the basic science knowledge of NPEV, this FOA is focused on basic research on non-polio enteroviruses A, B, C, and D with the intent of informing future vaccine and therapeutic development. Investigators are encouraged to develop multi-disciplinary and innovative ideas/approaches and develop applications that will advance knowledge to inform development of broad-spectrum antivirals and broadly active vaccines. Examples include, but are not limited to: <ul style="list-style-type: none"> • Understanding pathogenesis of enteroviruses A, B, C and D • Applying new innovative technologies, such as deep learning and single-cell analysis or developing platform technologies that are integral to inform broad-spectrum antiviral and/or pan-enterovirus vaccine development • Animal model development to understand the pathogenesis and to evaluate vaccine or therapeutic efficacy against non-polio enteroviruses 	Letter of Intent Due: 6/13/21 Proposal Due: 7/13/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-006.html#_Section_II_Award_1

127.	Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed) (NIH)	RFA-AI-21-007	<p style="text-align: center;">VACCINE DEVELOPMENT</p> <p>This initiative will support the design of novel TB vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. Emphasis is placed on high risk/high impact, cutting edge strategies for TB vaccine design that incorporate novel technologies and Mtb immunogens to expand the current global TB vaccine portfolio. Furthermore, applications from investigators new to the TB vaccine field as well as cross-disciplinary collaborations are encouraged. Proof-of-principle studies of candidate vaccines should include assessment of immunogenicity and preliminary efficacy in a relevant animal model. Research projects and studies may include, but are not limited to the following topics listed below:</p> <ul style="list-style-type: none"> • Novel platforms to induce protective mucosal immunity, including adaptive and innate immune responses. • Novel technologies to elicit durable cellular immunity against Mtb • TB vaccine approaches incorporating innovative antigen design strategies. • Development of novel vaccine delivery platforms, adjuvant and/or vaccine formulations. 	<p>Letter of Intent Due: 5/30/21</p> <p>Proposal Due: 6/30/21</p>	Up to \$2.1 million, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html#_Section_II._Award_1
128.	Pre-Announcement Enhancing Innovations in Advanced Manufacturing Technologies for Vaccines against Influenza and Emerging Infectious Diseases (FDA)	FOR-FD-21-006	<p>CBER seeks to support the application of novel technologies for advanced manufacturing of complex biologic products, and innovative analytical approaches to improve product manufacturing and quality through active research. One such technology is continuous manufacturing, defined as manufacturing using a continuous process, rather than a batch-process approach. This emerging technology has the potential to improve agility, flexibility, cost, and robustness in the manufacturing processes for complex biologics. In general, CBER seeks to enhance development of innovative technologies with the potential to address product shortages, improve product quality, and accelerate the time to market for complex biologics such as vaccines against influenza and other emerging diseases. The supported research will advance innovations in manufacturing by developing and making technologies accessible to industry in the near term, and by bridging the gaps between discoveries and the implementation by industry. Additionally, this research is intended to support advances in regulatory science that allow for development of science and risk-based guidelines to facilitate faster adoption of these innovative technologies.</p>	Estimated Post Date: Spring 2021	Up to \$500,000, per award	https://www.grants.gov/web/grants/view-opportunity.html?opId=331720

WOMEN'S HEALTH (2)						
129.	Notice of Special Interest (NOSI): Administrative Supplements for Research on Women's Health in the IDeA States (NIH)	NOT-GM-21-018 PA-20-272	This NOSI encourages research addressing issues of women's health with a focus on maternal and infant morbidity and mortality, including their underlying causes. Eligibility for this supplement program is limited to current awardees of the following NIGMS programs: (1) Centers of Biomedical Research Excellence program, which supports the establishment and development of innovative, state-of-the-art biomedical and behavioral research centers, (2) The IDeA Networks of Biomedical Research Excellence program, which supports a statewide biomedical research development network in each IDeA-eligible state and (3)The IDeA Program Infrastructure for Clinical and Translational Research which enhances the ability of IDeA state institutions and investigators to develop competitive clinical and translational research programs. Use FOA PA-20-272 to apply to this NOSI.	Proposal Due: 4/19/21	Up to \$200,000, for up to 1 year	https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-018.html https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section II. Award 1
OTHER (3)						
130.	NIH/NIOSH Support for Conferences and Scientific Meetings (R13/U13 Clinical Trial Not Allowed) (NIH)	PA-21-151 PAR-21-193	The purpose of the NIH Research Conference Grant (R13/U13) is to support high quality scientific conferences that promote occupational safety and health, NIOSH program priorities, and public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge, whether or not a published report results from such meeting. The NIH recognizes the value to members of the research community and all other interested parties in supporting such forums.	Letter of Intent Due: 3/12/21 7/12/21 Proposal Due: 4/12/21 8/12/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PA-21-151.html#_Section II. Award 1 https://grants.nih.gov/grants/guide/pa-files/PAR-21-193.html#_Section II. Award 1
131.	Preventing Violence Affecting Young Lives (PREVAYL) (CDC)	CDC-RFA-CE21-2104	The purpose of this funding is to address multiple forms of violence impacting adolescents and young adults, particularly in communities with high rates of violence, by implementing prevention approaches with an emphasis on the outer levels of the social-ecological model (i.e., community/societal levels). PREVAYL requires recipients to implement community/societal level strategies and approaches that address multiple forms of violence impacting adolescents and young adults, develop and/or enhance a jurisdictional violence prevention strategic plan, develop and implement an evaluation plan, develop a sustainability plan, and participate in a multi-sector coalition. In addition, this funding will address risk factors such as social determinants of health and racial inequity.	Proposal Due: 5/1/21	Up to \$250,000 per year, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?oppId=329981 (Full Announcement in Related Documents Tab)